PROTOCOL: SHP634 -402
TITLE: A Phase 4, Open- Label, Single -Center Clinical Study  of Extended use 
of rhPTH(1- 84) in Hy poparathy roidism
DRUG: rhPTH(1 -84)
IND 076514
BLA: 125511
SPONSOR Shire Human Genetic Therapies, Inc.
300 Shire Way , Lexington, MA 02421 USA
PRINCIPAL/
COORDINATING
INVESTIGATOR:, MD
PROTOCOL 
HISTORY:Original Protocol: 27 May 2016
This document contains confidential and proprietary information of Shire and is disclosed pursuant to 
confidentiality and non -disclosure obligations. This information should be used solely for the purposes for which 
it was provided and should not be copied, shared w ith, or disclosed to any third party without the express written 
consent of Shire.
For non-commercial use only
For non-commercial use only
 
   
SUMMAR Y OF CHANGES F ROM PREVIOUS VERSION
Not applicable. This is Version 1.0 of the protocol.
Shire 
SHP634-402 Protocol
CONFIDENTIAL 
Page 3 
27 May 2016
For non-commercial use only
For non-commercial use only
 
   
PRODUCT QUALITY  COMP LAINTS
Investigators are required to report investigational product quality  complaints to Shire within 24 
hours. This includes an y instances wherein the quality  or performance of a Shire product 
(marketed or investigational) does not meet expectations (eg, inadequate or faulty  closure, 
product contamination) or that the product did not meet the specifications defined in the 
application for the product (eg, wrong product such that the label and contents are dif ferent 
products). For instructions on reporting AEs related to product complaints, see Section 8.
Please use the information below as applicable to report the Product Quality Complaint:
Origin of Product Quality Complaint E-mail Address
North and South Am erica
European Union and Rest of World
Telephone numbers:
Shire
Lexington, MA (USA)
Shire 
SHP634-402 Protocol
CONFIDENTIAL 
Page 5 
27 May 2016
For non-commercial use only
 
   
TABLE OF  CONTENTS
PROTOCOL  SIGNATURE P AGE .................................................................................................2
SUMMARY OF CHANGES F ROM PREVIOUS VERSI ON........................................................3
EMERGENCY CONTACT I NFORMATION ................................................................................4
PRODUCT QUALITY COMP LAINTS ..........................................................................................5
TABLE OF CONTENTS .................................................................................................................6
LIST OF TABLES .........................................................................................................................10
LIST OF FIGURES .......................................................................................................................10
LIST OF APPENDICES ................................................................................................................10
ABBREVIAT IONS .......................................................................................................................11
STUDY SYNOPSI S
......................................................................................................................13
STUDY SCHEDULE ....................................................................................................................16
1.BACKGROUND INFORMATI ON.......................................................................................18
1.1 Indication and Current Treatment Options ...............................................................18
1.2 Product Background .................................................................................................19
1.2.1 Preclinical Information ..........................................................................................19
1.2.2 Clinical I nformation ...............................................................................................20
2.STUDY OBJECTIVES AND PURPOSE ..............................................................................22
2.1 Rationale for the Study .............................................................................................22
2.2 Study  Objectives ......................................................................................................22
2.2.1 Primary  Objectives .................................................................................................22
2.2.2 Secondary  Obje ctives .............................................................................................22
3.STUDY DESIGN ...................................................................................................................23
3.1 Study  Design and Flow Chart ..................................................................................23
3.2 Duration and Study  Completion Definiti on
.............................................................25
3.3 Sites and Regions .....................................................................................................25
3.4 Discussion of Study  Design .....................................................................................25
4.STUDY POPUL ATION.........................................................................................................27
4.1 Inclusion Criteria
................................ ................................ ................................ ......27
4.2 Exclusion Criteria ................................ ................................ ................................ .....27
4.3 Reproductive Potential ................................ ................................ ............................. 28
4.3.1 Female Contraception ............................................................................................28
4.3.2 Male Contraception ................................ ................................ ................................ 28
4.4 Discontinuation of Subjects ................................ ................................ ..................... 28
4.4.1 Subject Withdrawal Criteria ................................ ................................ .................. 28
4.4.2 Reasons for Discontinuation ................................ ................................ .................. 28
Shire 
SHP634-402 Protocol
CONFIDENTIAL 
Page 6 
27 May 2016
For non-commercial use only
 
   
4.4.3 Subjects “L ost to Follow -up” Prior to Last Scheduled Visit .................................29
5.PRIOR AND CONCOMITAN T TREATMENT ...................................................................30
5.1 Prior Treatment ........................................................................................................30
5.2 Concomitant Treatment ............................................................................................30
5.2.1 Permitted Treatment ...............................................................................................30
5.2.2 Prohibited Treatment .............................................................................................30
5.2.3 Active Vitamin D, Calcium, Native Vitamin D, and Magnesium 
Supplementation ....................................................................................................30
5.2.3.1 Active Vitamin D ...................................................................................30
5.2.3.2 Native Vitamin D ...................................................................................30
5.2.3.3
Calcium ..................................................................................................31
5.2.3.4 Magnesium .............................................................................................31
5.2.4 Thiazide Diuretics ..................................................................................................31
6.INVESTIGAT IONAL PROD UCT ........................................................................................32
6.1 Identity  of Investigational Product ...........................................................................32
6.1.1 Blinding the Treatment Assignment ......................................................................32
6.2 Administration of I nvestigational Product(s) ...........................................................32
6.2.1 Allocation of Subjects to Treatment ......................................................................33
6.2.2 Dosing ....................................................................................................................33
6.2.3 Unblinding the Treatment Assignment ..................................................................33
6.3
Labeling, Packaging, Storage, and Handling ...........................................................33
6.3.1 Packaging ...............................................................................................................33
6.3.2 Labeling .................................................................................................................33
6.3.3 Storage ...................................................................................................................34
6.3.4 Special Handling ....................................................................................................34
6.4 Drug Accountability .................................................................................................35
6.5 Subject Compliance ..................................................................................................35
7.
STUDY PROCEDURES........................................................................................................37
7.1 Study  Schedule ................................ ................................ ................................ ......... 37
7.1.1 Baseline Visit (Visit 1) ................................ ................................ ........................... 37
7.1.2 Treatment Period ................................ ................................ ................................ ....38
7.1.2.1 Visit 2, (Month 6)................................ ................................ ................... 38
7.1.2.2 Visit 3 (Month 12) ..................................................................................38
7.1.2.3 Visit 4 (Month 18) ................................ ................................ .................. 38
7.1.2.4 EOT Visit (Month 24) ................................ ................................ ............ 38
7.1.3 Additional Care of Subjects after the Stud y ................................ .......................... 38
7.2 Study  Evaluations and Procedures ................................ ................................ ........... 38
7.2.1 Demographic and Other Baseline Characteristics ................................ ................. 38
Shire 
SHP634-402 Protocol
CONFIDENTIAL 
Page 7 
27 May 2016
For non-commercial use only
 
   
7.2.2 Efficacy ................................ ................................ ................................ .................. 39
7.2.2.1 Biochemical Evaluations ........................................................................39
7.2.2.2 Hypoparathy roidism Multisy mptom Questionnaire ...............................39
7.2.2.3 Cognition Tool .......................................................................................39
7.2.2.4 FACIT Fatigue Scale ..............................................................................39
7.2.2.5 HADS Assessment .................................................................................39
7.2.2.6 Short Form Health Survey -
36 ................................................................39
7.2.2.7 Bone Mineral Densit y
............................................................................40
7.2.2.8 Bone Biops y
...........................................................................................40
7.2.2.9 .............................................................40
7.2.3 Safety .....................................................................................................................40
7.2.3.1
Adverse Event Collection.......................................................................40
7.2.3.2 Clinical L aboratory  Evaluations .............................................................41
7.2.3.3 Pregnancy  
Test .......................................................................................42
7.2.3.4 PTH Antibodies ......................................................................................42
7.2.3.5 Vital Signs ..............................................................................................43
7.2.3.6 Physical Examination .............................................................................43
8.ADVERSE AND SERIOUS ADVERSE EVENTS ASSES SMENT ....................................44
8.1
Definition of Adverse Events, Period of Observation, Recording of Adverse 
Events .......................................................................................................................44
8.1.1 Severity  Categorization ..........................................................................................44
8.1.2 Relationship Categorization ...................................................................................45
8.1.3 Outcome Categorization ........................................................................................45
8.1.4 Symptoms of the Disease Under Study .................................................................45
8.1.5 Clinical L aboratory  and Other Safet y Evaluations ................................................45
8.1.6 Pregnancy ...............................................................................................................46
8.1.7 Abuse, Misuse, Overdose, and Medication Error ..................................................46
8.2 Serious Adverse Event Procedures ..........................................................................47
8.2.1 Referen ce Safet y Information ................................ ................................ ................ 47
8.2.2 Reporting Procedures ................................ ................................ ............................. 47
8.2.3 Serious Adverse Event Definition ................................ ................................ ......... 48
8.2.4 Ser ious Adverse Event Collection Time Frame .....................................................48
8.2.5 Serious Adverse Event Onset and Resolution Dates .............................................48
8.2.6 Fatal Outcome ................................ ................................ ................................ ........ 49
8.2.7 Regulatory  Agency , Institutional Review Board, Ethics Committee, and Site 
Reporting................................................................................................................49
9.DATA MANAGEMENT AND STATISTICAL METHODS
................................ ............... 50
9.1 Data Collection ................................ ................................ ................................ ......... 50
9.2 Clinical Data Management ................................ ................................ ....................... 50
Shire 
SHP634-402 Protocol
CONFIDENTIAL 
Page 8 
27 May 2016
For non-commercial use only
 
   
9.3 Data Handling Considerations................................ ................................ .................. 50
9.4 Statistic al Analy sis Process ......................................................................................50
9.5 Planned Interim Anal ysis, Adaptive Design, and Data Monitoring Committee ......50
9.6
Sample Size Calculation and Power Considerations................................................51
9.7 Study  Population ......................................................................................................51
9.8 Efficacy  
Anal yses.....................................................................................................51
9.8.1 Primary  Efficacy  Endpoint ....................................................................................51
9.8.2 Secondary  Efficacy  Endpoints ...............................................................................51
9.8.3 Exploratory  Efficacy  Endpoints .............................................................................51
9.9 Safety  Anal yses........................................................................................................52
9.10 Other Anal yses.........................................................................................................52
9.10.1 Health
-related Quality  of L ife Anal yses................................................................53
10.SPONSOR’S AND I NVEST IGATOR’S RESPONSIBIL
ITIES...........................................54
10.1
Sponsor’s Responsibilities .......................................................................................54
10.1.1 Good Clinical Practice Compliance .......................................................................54
10.1.2 Public Posting of Study  Information ......................................................................54
10.1.3 Submission of Summary  of Clinical Study  Report to Competent Authorities 
of Member States Concerned and Ethics Committees ...........................................54
10.1.4 Study Suspension, Termination, and Completion
..................................................54
10.2 Investigator’s Responsibilities .................................................................................55
10.2.1 Good Clinical Practice Compliance .......................................................................55
10.2.2 Protocol Adherence and Investigator Agreement ..................................................55
10.2.3 Documentation and Retention of Records .............................................................56
10.2.3.1 Case Report Forms .................................................................................56
10.2.3.2 Recording, Access, and Retention of Source Data and Study  
Documents ..............................................................................................56
10.2.3.3 Audit/I nspection .....................................................................................56
10.2.3.4 Financial Disclosure ...............................................................................57
10.3 Ethical Considerations ..............................................................................................57
10.3.1 Informed Consent ...................................................................................................57
10.3.2 Institutional Review Board or Ethics Committee ................................ .................. 57
10.4 Privacy  and Confidentiality ................................ ................................ ...................... 58
10.5 Study  Results / Publication Policy ...........................................................................59
11.REFERENCES ................................ ................................ ................................ ....................... 61
Shire 
SHP634-402 Protocol
CONFIDENTIAL 
Page 9 
27 May 2016
For non-commercial use only
 
   
LIST  OF TABLES
Table 1-1: Schedule of Study  Assessments ....................................................................16
Table 6
-1: Recommended Adjustm ents for Active Vitamin D and Calcium 
Supplements ..................................................................................................32
LIST  OF FIGURES
Figure 3 -
1: Study  Design Flow Chart ..............................................................................24
LIST  OF APPENDICES
Appendix 1 Hypoparathy roidism Symptom Diary ....................................................62
Appendix 2 FACT -Cognitive Function ENG ............................................................67
Shire 
SHP634-402 Protocol
CONFIDENTIAL 
Page 10 
27 May 2016
 
   
ABBREVIA TIONS
ACSC albumin -corrected total serum calcium
AE adverse event
ALP alkaline phosphatase
ALT alanine aminotransferase
AST aspartate aminotransferase
-HCG beta-human chorionic gonadotropin
BLA Biologics License Application
CI confidence interval
CRA Clinical Research Associate
CRF case report form
CRO contract research organization
CSR clinical study  report
DXA dual-energy  x-ray absorptiometry
EC Ethics committee
ECG electrocardiogram
eCRF electronic case report form
eGRF estimated Glomerular Filtration Rate
EMA European Medicines Agency
EU Europe an Union
FACIT Functional Assessment of Chronic Illness Therapy
FACT -Cog Functional Assessment of Cancer Therap y -Cognitive Function
FDA Food and Drug Administration
FSH follicle -stimulating hormone
GCP Good Clinical Practice
HADS Hospital Anxiety  and Depression Scale
HIPAA Health Insurance Portability  and Accountability  Act
HPT Hypoparathy roidism
HRpQCT high-resolution peripheral quantitative computerized tomography
ICF informed consent form
ICH International Conference on Harmonisation
ICMJE International Committee of Medical Journal Editors
IRB Institutional Review Board
MedDRA Medical Dictionary  of Regulatory  Activities
Shire 
SHP634-402 Protocol
CONFIDENTIAL 
Page 11 
27 May 2016
 
   
mmHg millimeters of mercury
PTH Parathy roid hormone
QD once dail y
RBC red blood cell
rhPTH(1 -84) recombinant human p arathy roid hormone
SAE serious adverse event
SAP Statistical analy sis plan
SAS Statistical Analy sis Sy stem
SC subcutaneous
SF-36 36-item Short Form Health Survey
SOC system organ class
TEAE treatment -emergent adverse event
US United States
WBC white blood cell
Shire 
SHP634-402 Protocol
CONFIDENTIAL 
Page 12 
27 May 2016
 
   
STUDY  SYNOPSIS
Protocol num ber: SHP634 -402 Drug: rhPTH(1 -84)
Title of the study: A Phase 4, Open -Label, Single- Center Clinical Study of Extended use of rhPTH(1- 84) in 
Hypoparathyroidism
Number of subjects (total and for each treatm ent arm) :
The subject population anticipated in this study is up to 50 subjects. All subjects are exclusively from the core study 
(HEXT: The Hypoparathyroidism Studies, EXTended: The Effect of PTH on the Skeleton in Hypoparathyroidism) 
Protocol AAAE0544 at Columbi a University Medical Center, and w ill all receive active rhPTH(1 -84) treatment .
Investigator(s):
Single site located at:
Columbia University
New  York, NY 10032
Site(s) and Region(s): 
Columbia University
New  York, NY 10032
Study period (planned): 24 mon ths Clinical phase: 4
Objectives:
Prim ary:
To evaluate albumin -corrected serum calcium while on rhPTH(1 -84) treatment
Secondary:
To evaluate urinary calcium excretion and serum phosphate while on rhPTH(1 -84) treatment
To evaluate calcium and active vitam in D supplement doses while on rhPTH(1 -84) treatment
To evaluate disease- related symptoms, perception of cognitive function, and health -related quality -of-life 
associated with long -term rhPTH(1 -84) treatment
To evaluate the skeletal actions of rhPTH(1 -84):bone turnover (markers), architecture, and histology 
(biopsy)
Rationale:
Chronic hypoparathyroidism (HPT) is a life -long and irreversible disease for which the chronic administration of 
rhPTH(1 -84) is a potential treatment option. Thus, long -term safety and efficacy data are important in evaluating the 
proper use of this treatment option in clinical practice.
Investigational product, dose, and m ode of administration:
rhPTH(1 -84); 25, 50, 75, and 100 µg for once daily subcutaneous injection to the thigh v ia a multidose pen injector 
device. The dose w ill be individualized to achieve a serum calcium level in the lower half of the normal range.
Shire 
SHP634-402 Protocol
CONFIDENTIAL 
Page 13 
27 May 2016
 
   
Methodology: 
Subjects enrolled are currently or w ere previously enrolled in the core study (AAAE0544) and have mai ntained 
uninterrupted therapy with rhPTH(1 -84).Study visits will be scheduled every 6 months up to the 24 -month end of 
study visit. Specific procedures at each study visit are summarized in Table 1 - 1.A schematic of the study design is 
provided below :
Inclusion and exclusion criteria:
Inclusion Criteria:
The subject must meet all of the following criteria to be eligible
1.Subjects that are currently or previously enrolled in the core study (AAAE0544) and have maintained 
uninterrupted the rapy with rhPTH(1 -84) (transient interruptions of up to 1 month continuously off treatment 
may be allowed).
2.Signed and dated informed consent form (ICF).
3.Adult men and w omen 18 to 85 years of age.
4.History of hypoparathyroidism for at least 12 months prior to rhPTH(1 -84) treatment, defined by the 
requirement for supplemental calcium and/or active vitamin D to maintain serum calcium along with an 
undetectable or insufficient PTH concentration.
5.Able to perform daily subcutaneous self -injections of study medication (or have designee perform injection).
6.Willingness and ability to understand and comply with the protocol. Women must agree to pregnancy testing 
and acceptable methods of contraception, as detailed in the protocol.
Exclusion Criteria:
Subjects will be excluded from the study if anyof the following exclusion criteria are met:
1.The subject is treated or has been treated w ith any investigational drug, aside from rhPTH(1 -84), within 30 
days of consent.
2.As assessed by the investigator, the subject has a safe ty or medical issue that contraindicates participation 
in the study.
3.The subject and/or the subject’s parent(s) or legally -authorized representative(s) is unable to understand the 
nature, scope, and possible consequences of the study. 
4.The subject is unabl e to comply with the protocol, eg, uncooperative with protocol schedule, refusal to 
agree to all of the study procedures, inability to return for evaluations, or is otherwise unlikely to complete 
the study, as determined by the investigator or the medical monitor.
5.The subject is pregnant or lactating.
6.Subjects who are at increased baseline risk for osteosarcoma such as subjects w ith Paget’s disease of bone 
or unexplained elevations of alkaline phosphatase, subjects with hereditary disorders predisposing to 
osteosarcoma or subjects w ith a prior history of external beam or implant radiation therapy involving the 
skeleton.
Maximum duration of subject involvem ent in the study:
Each study visit has a threshold of ±1 month with a total treatment period of 24 mont hs. A follow -up phone call to 
assess safety will occur 30 days after the end of treatment visit.
Endpoints and Statistical Analysis: 
Prim ary Efficacy Endpoint:
Shire 
SHP634-402 Protocol
CONFIDENTIAL 
Page 14 
27 May 2016
 
   
Albumin -corrected serum calcium over time
Secondary Efficacy Endpoint(s):
Urinary calcium and serum phosphate over time
Calcium and active vitamin D supplement doses over time
HPT Disease -related symptoms (Multisymptom questionnaire), FACT -Cog assessment, FACIT (Fatigue 
Scale [Version 4]), and HADS (Hospital Anxiety and Depression Scale)
Health -related quality -of-life measured w ith SF -36 survey over time
Bone turnover (markers), architecture, and histology (biopsy) over time
Exploratory Efficacy Endpoint: 

Safety Endpoints:
AEs including SAEs
Symptoms of hypoparathyr oidism
Vital signs including body temperature, heart rate, respiratory rate, and blood pressure (systolic and 
diastolic)
Estimated Glomerular Filtration Rate (eGFR) and creatinine clearance
Measurements of antibodies to parathyroid hormone (PTH)
Laboratory safety data (eg, clinical chemistry, hematology, and urinalysis)
Although no formal hypotheses are being tested, 95% confidence intervals (CI) w ill be provided as appropriate. 
Continuous variables, including those assessed on a discrete scale, will be sum marized using descriptive statistics 
including number of subjects, mean, median, standard deviation, maximum, and minimum. For categorical 
variables, statistical summaries will include number of subjects and percentages.
Safety data, including laboratory t ests and vital signs assessments, will be summarized by visit. AEs will also be 
collected and summarized. Descriptive statistics will be calculated for quantitative safety data as w ell as for the 
difference from the SHP634 -402 baseline, if applicable. Freq uency counts will be compiled for classification of 
qualitative safety data (for example shift from baseline according to lab normal range, AEs related to treatment, 
level of severity, etc.).
Other Analyses:
A retrospective analysis of historical data capt ured from the medical records of subjects (eg, since the start of 
rhPTH(1 -84) treatment) will be conducted. Data collected will include but is not limited to, medical history and 
clinical laboratory data. There are no formal hypotheses testing for the retr ospective analysis. Descriptive statistics 
will be calculated for quantitative safety data as well as for the difference from the pre -rhPTH(1 -84) treatment 
baseline, if applicable.
Interim Analysis:
A retrospective analysis of historical data captured from the medical records of subjects (eg, since the start of 
rhPTH(1 -84) treatment) will be conducted. Data collected will include but is not limited to, medical history and 
clinical laboratory data. There are no formal hypotheses testing for the retrospective analysis. Descriptive statistics 
will be calculated for quantitative safety data as well as for the difference from the pre -rhPTH(1 -84) treatment 
baseline, if applicable.
Shire 
SHP634-402 Protocol
CONFIDENTIAL 
Page 15 
27 May 2016

 
   
STUDY  SCHEDULE
Table 1-1: Schedule of Study Assessments
Study Period BaselineMaintenance 
Dosing 
PeriodEnd of 
Treatm ent
Visit Visit 1 Visit 2 -4 EOT Visita
Study Month 0 6 12 18 24
Study Procedures ±1 m onth
Informed ConsentbX
Inclusion/Exclusion X
Medical history and demo graphy X
Prior/concomitant medications X X X X X
Physical examination X X X
Vital signscX X X X X
Hem atology X X
Serum chemistrydX X X X X
Serum TSH X
Serum pregnancy testeX
Urine pregnancy test X X X X X
FSH levelfX
Serum PTH antibodiesgX X X X X
Serum 25- hydroxyvitamin D X X X X X
Serum 1,25 -dihydroxyvitamin D X X X X X
Bone turnover markers X X X X X
Urinalysis (dipstick) X X
24-hour urinehX X X X
Bone mineral density DXA X X X X X
Bone mineral density H RpQCT X X X X X
Bone biopsy (optional) X
HPT multisymptom questionnaire X X X X X
FACT -Cog assessment X X X X X
SF-36 X X X
FACIT Fatigue Scale X X X X X
HADS assessment X X X X X
X X X X X
AE/SAE monito ring X X X X X
Dispense/Account for study drug X X X X X
Collection of unused study drug & injection pen X
Record any use of Calcium, Calcitriol, and/or 
Vitamin D supplementsX X X X X
Abbreviations: AE = Adverse event; DXA = dual -energy x -ray abso rptiometry; HPT = Hypoparathyroidism; 
SAE=Serious adverse event; SF -36 = 36 -Item Short Form Health Survey; HRpQCT = High -resolution peripheral 
quantitative computerized tomography.
a For subjects not continuing rhPTH[1 -84] treatment, see Section 7.1.3 .
b Remote consent allowed. Consent procedure must be complete prior to completing any Baseline assessments (can 
occur at Baseline Visit as long as complete prior to assessments) . 
c Vitals signs include: blood pressure, heart rate, body temperature, and respiration rate.
d Serum chemistry panel includes sodium, potassium, chloride, bicarbonate, blood urea nitrogen, creatinine, calcium, 
phosphate, magnesium, albumin, ALT, AST, and ALP.
e Pregnancy tests for females of childbearing potential.
f FSH level required for newly menopausal women.
Shire 
SHP634-402 Protocol
CONFIDENTIAL 
Page 16 
27 May 2016

 
   
Table 1-1: Schedule of Study Assessments
Study Period BaselineMaintenance 
Dosing 
PeriodEnd of 
Treatm ent
Visit Visit 1 Visit 2 -4 EOT Visita
Study Month 0 6 12 18 24
Study Procedures ±1 m onth
g Blood samples for antibody testing should be collected prior to dosing with PTH[1 -84]. Any subject with newly 
developed PTH -specific antibodies at the end of treatment v isit may require follow  up. This will be discussed as 
necessary by the PI and medical monitor on a case -by-case basis.
h 24-hour urine collection includes urine calcium, creatinine, phosphate, magnesium and sodium analyses. Urine 
volume will be recorded. T he 24 -hour urine collections should generally be performed by the subject w ithin 2 weeks 
prior to or w ithin 2 days follow a study visit. These 24 -hour urine collections may be analyzed in a local laboratory. 
To the greatest extent possible, the same labora tory should analyze the 24 -hour urine collections throughout the 
study. Results from the last 24 -hour urine collection obtained in Columbia protocol AAAE0544 w ill be used as the 
baseline assessment in this study. At the beginning of the study, the investig ator should recommend an 
individualized target dietary (non -supplement) calcium intake for each subject to ingest consistently throughout the 
study on 24 -hour urine collection days. When collecting 24 -hour urine specimens subjects should be instructed to 
take their currently prescribed calcium, vitamin D (both parent and active) and rhPTH(1 -84) doses .
Shire 
SHP634-402 Protocol
CONFIDENTIAL 
Page 17 
27 May 2016
 
   
1. BACKGROUND INFORMATI ON
Hypoparathy roidism (HPT) is a rare disorder characterized by  hypocalcemia in the presence of 
inappropriatel y low or undetectable l evels of circulating parathy roid hormone (PTH) 
(Avioli 1974; Haussler and Cordy  1982, Shoback 2008) The most frequent cause of 
hypoparathy roidism is resection of, or damage to, parathy roid glands during neck surgery  
(eg,thyroidectom y), although multiple other genetic, metabolic and congenital etiologies exist. 
Hypoparathy roidism occurs in about 0.9% to 6.6
% of thy roidectomies, with higher rates 
associated with more complicated interventions ( Shoback 2008; Thomusch et al. 2003 ; 
Zarnegar et al. 2003; Page andStrunski 2007 ). In 1 y ear spanning 2007 -2008 
(Powers etal.2013) the incidence of chronic hy poparathy roidism ( ≥6 months) was said to be 
approximately  60,000 subjects in the United States (US), which rises to approximately  117,000 if 
the transient h ypoparathyroid population is included ( ≤6 months). The same authors sug gest that, 
of those 117,000 transient hy poparathy roid subjects, about 5% will become chronic.
Parathy roid hormone is an 84 -amino acid protein that is secreted b y the parathyroid glands. PTH 
has a variety  of important phy siological functions that are outlin ed below to explain the effects 
of absent or deficient PTH levels. Parath yroid hormone functions to help regulate bone 
metabolism and serum levels of calcium and phosphate. In general, if serum calcium 
concentrations decrease, the parath yroid glands conseq uently  increase PTH secretion, and, if 
serum calcium concentrations increase, the parathy roid glands consequently  reduce PTH 
secretion. The parathy roid glands sense the level of extracellular calcium at the surface of the 
parath yroid cell and adjust the sy nthesis and secretion of PTH accordingl y. 
Acute s ymptoms of hy poparathy roidism, linked mainly  to the hy pocalcemia, are generall y 
reversible. The key  symptoms associated with hy pocalcemia involve mainly  the neuromuscular 
system: numbness, paresthesias, twi tching, and tetany . More serious and potentially  life 
threatening effects of h ypocalcemia such as seizures, cardiac arrh ythmias, cardiom yopath y and 
laryngeal spasm are also recognized in hy poparathy roidism ( Behaghel and Donal 2011 ). 
Hypoparathy roidism has also been linked to effects on mood and ideation ( Arlt et al. 2002 ;
Velasco et al. 1999 ).
The kidney s are especially  vulnerable in subjects with hy poparathy roidism. Circulating PTH 
promotes renal calcium reabsorption, especially  at the level of the distal convoluted tubule 
(Blaine et al. 2015 ). In the absence of PTH, calcium can be over -excreted through the kidney s 
(Shoback 2008
), leading to hy percalciuria which, together with a high- calcium -phosphate 
product, can potentiall y lead to nephrocalcinosis and kidney  stones and, ultimately , to renal 
impairment ( Blaine et al. 2015 ).
For further details see the recombinant human PTH (rhPTH[1-84]) investigator brochure.
1.1 Indication and Current Treatment Options 
Prior to 2015, in the absence of an approved PTH replacement therap y, management of 
hypoparathy roidism consisted of supplemental oral calcium and active vitamin D in 
pharmacological doses sufficient to maintain the serum calcium level without the disabling 
symptoms of hy pocalcemia. I n order to improve t he absorption of calcium from the 
Shire 
SHP634-402 Protocol
CONFIDENTIAL 
Page 18 
27 May 2016
 
   
gastrointestinal tract, pharmacological supplementation with acti ve forms of vitamin D 
(eg,1,25- dihydroxyvitamin D 3[1,25(OH) 2D3], calcitriol, 1,25 -dihydroxycholecalciferol or α-
calcidol [1(OH)D 3]) is also required. Since PTH also functions in the kidney  to stimulate the 
conversion of 25(OH)D 3, the major circulating form of vitamin D, to the active vitamin D 
hormone (1,25[OH] 2D3), the relative lack of circulating PTH results 
in a reduction of the 
production of active vitamin D. Thus, exogenous active vitamin D overcomes the sy nthetic block 
in endogenous production of the active vitamin D hormone in hy poparathy roidism. Together, 
supplemental oral calcium and active vitamin D ha ve formed the mainstay  of current treatment 
of subjects with hy poparathy roidism. The additional calcium load that results from 
supplementation with exogenous calcium and active vitamin D contributes to the hy percalciuria 
and renal risks often noted in pati ents with hy poparathy roidism.
In an effort to limit the extent and effect of h ypercalciuria, thiazide diuretics can be helpful since 
they promote renal calcium reabsorption. However, thiazides are associated with their own 
adverse events (AEs) including h ypokalemia and, more importantly , have no proven long -term 
effect to reduce h ypercalciuria or kidney damage or improve the safety profile in this patient 
population ( Shoback 2008). Although an accepted adjunct to the use of calcium and active 
vitamin D in hy poparathyroidism, thiazides are prescribed to onl y a minority  of hypoparath yroid 
patients.
The investigational product (rhPTH[1- 84]) is a recombinant human PTH that is identical in 
structure to endogenous human PTH, a single -chain poly peptide consisting of 84 amino acid 
residues and is manufactured using a strain of Escherichia coli modified b y recombinant DNA 
technology . rhPTH(1- 84) was approved for marketing in the US on 23 January  2015 under the 
brand name Natpara®as a once -daily  injectable dose as an adjunct to calcium and vitamin D to 
control hy pocalcemia in patients with hy poparathy roidism.
1.2 Product Background 
1.2.1 Preclinical Information
A total of 46 in vivo studies in mouse, rat, rabbit, dog, and rhesus and cy nomolgus monkey s 
have evaluated the pharmacokinetics, pharmacody namic s and toxicology  of rhPTH(1- 84) at 
doses ranging from 0.1 to 10,000 μg/kg given as single doses or as dail y doses for up to 2 years. 
In the vast majority  of studies, rhPTH(1 -84) was administered by  subcutaneous (SC) injection, 
the intended route of adminis tration of rhPTH(1-84) in humans. A total of 7 in vitro
pharmacology  and toxicology  studies have been performed.
In male and female rats, the administration of PTH was associated with an increase in the 
incidence of osteosarcoma. These data were interprete d as an increased risk for osteosarcoma in 
the clinic. Therefore, administration of rhPTH(1-84) should be avoided in subjects who are 
considered to be at increased risk for osteosarcoma (including those with Paget’s disease of bone 
or unexplained elevation s of alkaline phosphatase, subjects with hereditary disorders 
predisposing to osteosarcoma or subjects with a history of prior external beam or implant 
radiation therap y involving the skeleton).
Shire 
SHP634-402 Protocol
CONFIDENTIAL 
Page 19 
27 May 2016
 
   
Currently  available results from animal reproductive toxicolo gy studies suggest that 
rhPTH(1 -84) is not associated with significant fetal or neonatal toxicity ; however, the safet y of 
rhPTH(1 -84) in pregnant or nursing women is not established.
For full details see the rhPTH(1- 84) investigator brochure.
1.2.2 Clinical Info rmation
Study  CL1 -11-040 (REPLACE) was a double -blind, placebo controlled study  of once daily  
(QD) SC administration of 50 μg to 100 μg of rhPTH(1 -84). The 3 -tiered primary  endpoint 
included 
≥ 50% reduction from baseline in oral calcium supplementation, ≥ 50% reduction from 
baseline in active Vitamin D, and albumin- corrected total serum calcium (ACSC) concentration 
maintained or normalized compared to baseline (not exceeding upper limit of normal). The 
3-tiered endpoint was met in 54.8% of rhPTH(1- 84) subj ects compared to 2.5% of placebo 
subjects (p<0.001). Long -term, open
-label studies have supported these findings with subjects 
maintaining the ph ysiologic benefit derived from rhPTH(1- 84) treatment. One extension study , 
PAR -C10-008 (RACE), is ongoing with some subjects receiving treatment for more than 3 years.
In clinical trials, rhPTH(1- 84) significantl y reduced the serum calcium -phosphate product. In 
these studies, hy percalciuria was defined as an excretion of calcium in the urine greater than 
300mg per 24 hours. Data from the REPLACE Study  and the long -term open label study , RACE, 
show that rhPTH(1- 84) has a calcium -sparing effect, consistent with the reduction of urinary  
calcium excretion seen in a previous pharmacokinetic/pharmacod ynamic study  (C09-002 ) of 
single dose administration of rhPTH(1 -84) in subjects with hy poparathy roidism in comparison 
with calcitriol administration.
The Phase 3 clinical study , REPLACE, was the largest, randomized, placebo controlled clinical 
study  conducted in hy poparathy roidism population and was the pivotal study  demonstrating that 
rhPTH(1 -
84) is effective in maintaining serum calcium levels and enabling significant decreases 
in active vitamin D and oral calcium doses. REPLACE also established the rhPTH(1 -84) dose 
and dose titration and evaluated the ph ysiologic effects of PTH replacement on serum calcium, 
serum phosphate, urinary calcium excretion and bone turnover markers. Eight y-four subjects 
were evaluated in the active treatment group and 40 subjects received placebo. S ubjects received 
at a flexible dose range of 50 to 100 μg SC in the thigh once dail y for 6 months. The study met 
the primary  efficacy  triple endpoint, with a statistically  higher responder rate (54.8%) versus 
placebo (2.5%). To meet the primary  endpoint a subject had to fulfill all 3 conditions as follows: 
a 50% or greater reduction in oral calcium requirement, a 50% or greater reduction in active 
vitamin D therap y and an ACSC concentration that was maintained within a range of 7.5 to 10.6 
mg/dL.
A review o f safety data across the hy poparathy roidism program indicated that rhPTH(1 -84) 
administered in the dose range of 25 to 100 μg SC QD is safe for use for the treatment of 
hypoparathy roidism. Very common adverse reactions (ie, reported in at least 1 in every  10 
subjects) included h ypocalcemia, h ypercalcemia, headaches, diarrhea, vomiting, and 
hypercalciuria. Common adverse reactions (ie, reported in at least 1 in every  100 subjects, but 
less than 1 in every  10 subjects) included hy pomagnesemia, anxiety  symptom s, palpitations, 
flushing, coughing and associated s ymptoms, neck pain, pollakiuri a, chest pain, thirst, blood 
25-hydroxy cholecalciferol decreased, and blood alkaline phosphatase increased.
Shire 
SHP634-402 Protocol
CONFIDENTIAL 
Page 20 
27 May 2016
 
   
There was no suggestion that rhPTH(1- 84) causes drug -induced liver injury in humans. There 
were no renal -related AEs or abnormalities in renal function tests or urinalysis tests in clinical 
studies apart from changes expected from the mechanism of action of rhPTH(1 -84). Despite 
significant increases in total serum calciu m levels and improved calcium homeostasis, treatment 
with rhPTH(1- 84) did not result in worsening of hy percalciuria. 
Because of the potential risk of osteosarcoma, rhPTH(1 -84) is recommended only  for subjects 
who cannot be well controlled on calcium supplements and active forms of vitamin D alone.
Additional risks include extensions of the pharmacologic effects of PTH including 
hypercalcemia. Post -treatment hy pocalcemia following the abrupt withdrawal of rhPTH(1 -84) 
can be particularl y problematic. Followi ng sustained withdrawal of rhPTH(1- 84), serum calcium 
levels must be carefull y monitored with reinstatement of appropriate dosages of oral calcium and 
active vitamin D. No on -treatment events of h ypocalcemia occurred following incidental missed 
doses of rhPTH(1- 84) during any  of the clinical studies, however subjects should be advised to 
take their rhPTH(1 -84) dose as soon possible following a missed dose and to take oral calcium.
Alway s refer to the latest version of the rhPTH(1 -84) investigator’s brochure for the overall 
risk/benefit assessment and the most accurate and current information regarding the drug 
metabolism, pharmacokinetics, efficacy  and safety  of rhPTH(1 -84).
Shire 
SHP634-402 Protocol
CONFIDENTIAL 
Page 21 
27 May 2016
 
   
2. STUDY OBJECTIVES AND PURPOSE
2.1 Rationale for the Study
Recombinant human parathy roid hormone has been developed as an adjunct to calcium and 
vitamin D to control hy pocalcemia in h ypoparathyroidism subjects who cannot be well 
controlled with calcium and vitamin D supplementation alone. Although the development of a 
novel therapeutic agent fo r the treatment of h ypoparath yroidism is encouraging, it is important to 
gain knowledge about the efficacy  and safet y of long -term use of rhPTH(1 -84) due to the chronic 
nature of the condition. 
The AAAE0544 cohort has the longest known duration of rhPTH(1- 84) therapy  for the treatment 
of hy poparathy roidism to date. This protocol is designed to extend this experience and to provide 
additional data on the long -term safety  and efficacy  of rhPTH(1 -84).
2.2 Study Objectives 
2.2.1 Primary Objectives 
To evaluate albumin- corrected serum calcium while on rhPTH(1 -84) treatment
2.2.2 Secondary Objectives
To evaluate urinary  calcium excretion and serum phosphate while on rhPTH(1 -84) treatment
To evaluate calcium and active vitamin D supplement doses while on rhPTH(1 -84) treatment 
To evaluate disease -related sy mptoms, perception of cognitive function, and health -related 
quality -of-life associated with long -term rhPTH(1- 84) treatment.
To evaluate the skeletal actions of rhPTH(1 -84): bone turnover (markers), architecture, and 
histology (biopsy )
Shire 
SHP634-402 Protocol
CONFIDENTIAL 
Page 22 
27 May 2016
 
   
3. STUDY DESIGN
3.1 Study Design and Flow Chart
Protocol SHP634 -402 is a single -center, open -label, single arm, Phase 4 study  of rhPTH(1- 84) 
treatment in adult subjects (up to 50 subjects) diagnosed with hy poparathy roidism. 
Pre-study  treatment, laborat ory data, and medical history  information for enrolled subjects will 
be verified. 
Subjects will be treated with rhPTH(1- 84) for a two -year treatment period with study  visits 
scheduled every  6(±1) months. 
A schematic representation of the study  design is provided in Figure 3-1. 
Shire 
SHP634-402 Protocol
CONFIDENTIAL 
Page 23 
27 May 2016
   
Figure 3-1: Study Design Flow Chart
Eligible
SubjectsInformed 
Consent / 
Baseline 
(Visit 1)6 months         12 months                 18 months      24 months            30 days
    Vi sit 2                 Visit 3  Visit 4       Visit 5(EOT)            Follow -upTreatment Period
Shire 
SHP634-402 Protocol
CONFIDENTIAL 
Page 24 
27 May 2016
 
   
3.2 Duration and Study Completion Definition
The subject's maximum duration of pa rticipation in the study is approximately  25 months. The 
study  Completion Date is defined as the date the final subject completes their final protocol -
defined assessment. Please note that this includes the follow -up phone contact 30 day s following 
the EOT( Month 24) visit. 
3.3 Sites and Regions
This is a single -center study  that will be conducted at Columbia University  Medical Center, New 
York, NY.
3.4 Discussion of Study Design
This protocol is only  intended for those subjects who participated and were treated in the 
AAAE0544 study . Limiting enrollment to subjects from the core study  (AAAE0544) will allow 
this study  to provide long- term safety  and efficacy  data. 
Administration via injection to the thigh has been shown to be a safe and effective delivery  
method of rhPTH(1- 84). Dosing is based upon previous exposure and the recommended dosing 
in the rhPTH(1- 84) package insert. The selected dose should reduce calcitriol and oral calcium 
(carbonate or citrate) supplementation to as low as safel y possible while maintain ing total serum 
calcium levels. All subjects will have their total serum calcium checked by  a local laboratory  as 
outlined in the Schedule of Study  Assessments ( Table 1 -1). Subjects may  have their 
rhPTH(1 -84) dose increased in increments of 25 µg to a maxi mum of 100 µg SC QD b y the 
investigator no more frequently  than 4 week intervals during the stud y, with the goal of 
achieving or maintaining total serum calcium levels in the range of 8.0 to 9.0 mg/dL if clinicall y 
appropriate. The rhPTH(1 -84) dose may  be adjusted downward at an y time as needed to 
maintain appropriate serum calcium levels (approximately  8.0 to 9.0 mg/dL) or due to an y safety 
concerns.
Adjustment of supplemental calcium and calcitriol regimens will be based on serum calcium 
levels, with the goal to be a reduction or removal of cal citriol treatment to the maximum degree 
clinically  possible and to decrease the prescribed oral calcium supplementation to ≤500 mg 
daily . 
Subjects generall y should have blood draws to assess total serum calcium levels (which may  be 
performed locall y) 3to 5 day s after ANY dose adjustment of rhPTH(1
-84), after any  significant 
change in doses of calcium and/or and calcitriol supplements, or at an y other time at the 
discretion of the investigator. Results of local total serum calcium levels will be entered o n the 
electronic case report form (eCRF). 
During the week following the last visit (End of Treatment or earl y termination visit), subjects 
who are discontinuing rhPTH(1 -84) treatment (ie, those who are NOT continuing on commercial 
Natpara) will have oral calcium and/or active vitamin D adjusted to compensate for the cessation 
of rhPTH(1-84). Their total serum calcium levels will be checked locall y 3 to 5 days after the last 
dose of study  medication. Subjects will also be scheduled for a follow -up clinic vi sit at the end of 
this week in order to have serum calcium and phosphate checked.
Shire 
SHP634-402 Protocol
CONFIDENTIAL 
Page 25 
27 May 2016
 
   
Approximately  30 day s following the End of Treatment visit, subjects will be contacted by  
telephone in order to assess AEs/serious AEs (SAEs). 
Shire 
SHP634-402 Protocol
CONFIDENTIAL 
Page 26 
27 May 2016
 
   
4. STUDY POPULATION
Each subject must participate in the informed consent process and provide written informed 
consent before an y procedures specified in the protocol are performed. Subjects in this protocol 
are restricted to those who were treated in the core study  (AAAE0544). Approximat ely 50 
subjects are expected to enroll in this study .
4.1 Inclusion Criteria
The subject must meet allof the following criteria to be eligible for the study :
1. Subjects that are currently  or previousl y enrolled in the core study  (AAAE0544) and have 
maintained uninterrupted therap y with rhPTH(1 -84) (transient interruptions of up to 1 
month continuously  off treatment may  be allowed).
2.Signed and dated informed consent form (ICF).
3.Adult men and women 18 to 85 y ears of age.
4.History  of hypoparath yroidism for at least 12 months prior to rhPTH(1-84) treatment, 
defined b y the requirement for supplemental calcium and/or active vitamin D to maintain 
serum calcium along with an undetectable or insufficient PTH concentration.
5.Able to perform daily  SC self -injections of study  medication (or have designee perform 
injection).
6.Willingness and ability  to understand and comply with the protocol. Women must agree to 
pregnancy  testing and acceptable methods of contraception, as detailed in the protocol.
4.2 Exclusion Criteria
Subjects wi ll be excluded from the study  if any  of the following exclusion criteria are met:
1.The subject is treated or has been treated with an y investigational drug, aside from 
rhPTH(1 -84), within 30 day s of consent.
2.As assessed b y the investigator, the subject has any safet y or medical issues that 
contraindicate participation in the study .
3.The subject and/or the subject’s parent(s) or legally -authorized representative(s) are 
unable to understand the nature, scope, and possible consequences of the study . 
4.The subject is unable to comply  with the protocol, eg, uncooperative with protocol 
schedule, refusal to agree to all of the study  procedures, inability  to return for evaluations, 
or is otherwise unlikel y to complete the study, as determined b y the investigator or the
medical monitor.
5.The subject is pregnant or lactating.
6.Subjects who are at increased baseline risk for osteosarcoma such as subjects with Paget’s 
disease of bone or unexplained new elevations of alkaline phosphatase, subjects with 
hereditary  disorders pre disposing to osteosarcoma or subjects with a prior history  of 
external beam or implant radiation therap y involving the skeleton.
Shire 
SHP634-402 Protocol
CONFIDENTIAL 
Page 27 
27 May 2016
 
   
4.3 Reproductive Potential
4.3.1 Female Contraception
Women who are postmenopausal (absence of menses for at least 1 y ear) and women who are 
surgically  sterilized (e g, tubal occlusion, hysterectomy, bilateral salpingectomy) can be enrolled. 
Women of childbearing potential must have a negative pregnancy  test and agree to use medicall y 
acceptable methods of contraception for the duration of t he study  with pregnancy  testing at every  
scheduled visit. 
Medically  acceptable methods of contraception include: true sexual abstinence (not having any  
type of intercourse or sex play  with a male partner); hormonal methods of contraception (oral, 
injected , vaginal rings, patch, implanted, etc.); placement of an intrauterine device or intrauterine 
system; barrier methods of contraception (condom or occlusive diaphragm or cervical/vault caps) 
with spermicidal foam/gel/film/cream/suppository . Women whose part ner is a woman or whose 
partner is a man with a history  of vasectom y are exempt.
4.3.2 Male Contraception
Not Applicable.
4.4 Discontinuation of Subjects
A subject may  withdraw from the study  at any  time for an y reason without prejudice to their 
future medical care by the phy sician or at the institution. The investigator or sponsor may  
withdraw the subject at any  time (eg, in the interest of subject safet y). The investigator is 
encouraged to discuss withdrawal of a subject from investigational product [rhPTH(1 -84)] w ith 
the medical monitor when possible.
If investigational product is discontinued, regardless of the reason, the evaluations listed for End 
of Treatment ( EOT) Visit are to be performed as completely  as possible. Comments 
(spontaneous or elicited) or complaints made b y the subject must be recorded in the source 
documents and as AEs, as applicable. The reason for termination, date of stopping rhPTH(1 -84) 
and the total amount of rhPTH(1-84) taken must be recorded in the electronic case report form 
(eCRF) and s ource documents.
Subjects who discontinue will not be replaced. 
4.4.1 Subject Withdrawal Criteria
Subjects can withdraw from the study  at an y time for an y reason. 
4.4.2 Reasons for Discontinuation
The reason for withdrawal must be determined b y the investigator and recorded in the subject’s 
medical record and on the eCRF. If a subject is withdrawn for more than 1 reason, each reason 
should be documented in the source document and the most clinically  relevant reason should be 
entered on the eCRF. Reasons for discontin uation include but are not limited to:
Shire 
SHP634-402 Protocol
CONFIDENTIAL 
Page 28 
27 May 2016
 
   
Completed
Adverse event
Protocol deviation
Withdrawal by  subject
Lack of efficacy
Lost to follow -up
Other (If “Other” is selected, the investigator must specify  on the eCRF: Examples are 
provided below)
Death
Physician decision
Pregnancy
Site terminated by  sponsor
Study  terminated by  sponsor
4.4.3 Subjects “Lost to Follow-up” Prior to Last Scheduled Visit
A minimum of 3 documented attempts must be made to contact an y subject lost to follow -up at 
any time point prior to the l ast scheduled contact (office visit or telephone contact). At least 1 of 
these documented attempts must include a written communication sent to the subject’s last 
known address via courier or mail (with an acknowledgement of receipt request) asking that th ey 
return to the site for final safet y evaluations and return any unused investigational product.
Shire 
SHP634-402 Protocol
CONFIDENTIAL 
Page 29 
27 May 2016
 
   
5. PRIOR AND CONCOMITAN T TREATMENT
All non- study  treatment, including but not limited to herbal treatment, vitamins, behavioral 
treatment, non -pharmacological tr eatment (such as psy chotherap y), as appropriate, received 
within 30 day s prior to the Baseline Visit (Visit 1) (or pharmacokinetic equivalent of 5 half-lives, 
whichever is longer) and through the final study  contact (including protocol defined follow -up 
period) must be recorded on the appropriate eCRF page.
5.1 Prior Treatment
Prior treatment includes all treatment, including but not limited to herbal treatment, vitamins, 
behavioral treatment, non- pharmacological treatment (such as ps ychotherapy), as appropriat e as 
of the time of enrollment in Study  SHP634- 402. Prior treatment information must be recorded on 
the appropriate eCRF page. All available active vitamin D and calcium supplement doses from 
the beginning of rhPTH(1- 84) will be recorded.
5.2 Concomitant Treat ment 
Concomitant treatment refers to all treatment taken between the dates of the first dose of 
rhPTH(1 -84) and the end of the follow -up period in the SHP634
-402 study , inclusive. 
Concomitant treatment information must be recorded on the appropriate eCRF page.
5.2.1 Permitted Treatment
Any treatment for an existing or obtained condition(s) will be permitted. Active vitamin D, 
native vitamin D, calcium and magnesium supplementation, and thiazide use are permitted. Prior 
treatment with rhPTH(1 -84) is permitted.
5.2.2 Prohibited Treatment
The use of an y other investigational product within 30 day s prior to study enrollment or at any  
time during the trial is prohibited. Additionally , any  medication that affects bone metabolism (eg, 
selective estrogen receptor modulators, c alcitonin, bisphosphonates) and any  other 
investigational products are prohibited while on rhPTH(1-84) treatment. 
5.2.3 Active Vitamin D, Calcium, Native Vitamin D, and Magnesium 
Supplementation
5.2.3.1 Active Vitamin D
Subjects enrolled in this study  may  be taking act ive vitamin D to control serum calcium levels. 
Prior and concomitant prescribed doses of calcitriol will be entered on the appropriate eCRF. 
5.2.3.2 Native Vitamin D 
Subjects should receive native vitamin D to maintain the subject’s serum 25(OH) vitamin D level
in the normal range ( ≥ 30 ng/ml and ≤ the upper limit of normal for the laboratory ). Prior and 
concomitant doses of native vitamin D must be recorded on the appropriate eCRF.
Shire 
SHP634-402 Protocol
CONFIDENTIAL 
Page 30 
27 May 2016
 
   
5.2.3.3 Calcium
Subjects enrolled in this study  may  be taking oral calcium supplements ( either calcium carbonate 
or calcium citrate). Prior and concomitant prescribed doses of calcium will be entered on the 
appropriate eCRF. 
In the case that extra calcium supplementation is taken b y the subject due to symptoms of 
hypocalcemia, the dose/time and associated sy mptoms should be recorded by  the subject in a 
diary . 
5.2.3.4 Magnesium 
Magnesium is required for normal parathy roid function and disordered magnesium levels can 
exacerbate h ypoparathy roidism. Subjects with low serum magnesium may  receive 
supplem entation to keep the serum magnesium level in the normal range. Prior and concomitant 
doses of magnesium must be recorded on the appropriate eCRF.
5.2.4 Thiazide Diuretics
Subjects in this study  may  be taking thiazide diuretics (hy drochlorothiazide or chlorthali done) to 
limit the extent and effect of hy percalciuria. Prior and concomitant prescribed doses of thiazide 
diuretics will be entered on the appropriate eCRF.
Shire 
SHP634-402 Protocol
CONFIDENTIAL 
Page 31 
27 May 2016
 
   
6. INVESTIGATIONAL PROD UCT
6.1 Identity of Investigational Product
The investigational product is rhPTH(1-84), which will be provided as a multiple dose, dual 
chamber, glass cartridge containing a sterile l yophilized powder and a sterile diluent for 
reconstitution at doses of 25µg, 50µg, 75µg, and 100µg. The investigational product in the 
cartridge must be mi xed using the provided mixing apparatus, and only  administered via the 
injector pen, which is also provided. Additional information related to the investigational 
product, including preparation and administration, is provided in the current rhPTH(1 -84) 
investigator brochure, and in an investigational product preparation and administration manual 
that will be provided.
No additional investigational product will be supplied. It is expected that subjects will continue 
to take their own supplemental oral calcium and vitamin D (except when instructed to hold at the 
times indicated in the current protocol) and that any  products required for emergency  treatment, 
eg, fluid or calcium replacement, be provided b y the study ph ysician.
6.1.1 Blinding the Treatment Assignment
This is an open -label single -arm study where all subjects will be administered study drug; 
therefore, no blinding will occur.
6.2 Administration of Investigational Product(s)
The following instructions describe how to administer the investigational product:
Adjust dose of active vitamin D or calcium supplement or both based on serum calcium value 
and clinical assessment (ie, signs and s ymptoms of hy pocalcemia or hy percalciuria). Suggested 
adjustments to active vitamin D and calcium supplement based on serum cal cium levels are 
provided in Table 6-1.
Table 6-1: Recommended Adjustments for Active Vitamin D and Calcium Supplements
Adjust First Adjust Second
Serum Calcium Active Vitamin D Forms Calcium Supplement
Abovethe Upper Limit of 
Normal (10.6 mg/dL)Decrease or Discontinue * Decrease
Greater than 9 mg/dL and below 
the Upper Limit of Normal (10.6 
mg/dL)Decrease or Discontinue *No change or decrease if active 
vitamin D has been discontinued
Less than or equa l to 9 mg/dL 
and above 8 mg/dLNo change No change
Lowers than 8 mg/dL Increase Increase
*Discontinue in patients receiving lowest available dose
Shire 
SHP634-402 Protocol
CONFIDENTIAL 
Page 32 
27 May 2016
 
   
6.2.1 Allocation of Subjects to Treatment 
This is an open -label, single -center study  where all subjects will rec eive rhPTH(1 -84).
6.2.2 Dosing
The dose of rhPTH(1-84) will be individualized based on SCAC and 24- hour calcium urinary  
excretion. The recommended rhPTH(1 -84) dose will be the minimum dose required to prevent 
both hy pocalcemia and hypocalciuria. This dose will g enerall y be the dose that maintains SCAC 
within the lower half of the normal range (ie, between 8 and 9 mg/dL) without the need for 
active forms of vitamin D and with calcium supplementation sufficient and individualized to 
meet the patient’s dail y require ments. 
The doses of rhPTH(1-84), active vitamin D, and calcium supplements will be prescribed on an 
individual basis. Dosing guidelines found in the US package insert will be used but may  be 
individualized at the discretion of the investigator. 
Doses of active forms of vitamin D and calcium supplements will be adjusted when using 
rhPTH(1 -84).
6.2.3 Unblinding the Treatment Assignment
Not Applicable.
6.3 Labeling, Packaging, Storage, and Handling
6.3.1 Packaging
The study  site will receive open label supplies of investigational product , injection pens and 
mixing devices required for dosing.
Each subject will receive 2 pens for use during the study  period and sufficient cartridges to 
provide daily  doses for the duration of the study . Drug cartridges will be provided in kits
containing 8 cartridges each and each kit will be sufficient for up to 16 weeks of treatment. Each 
cartridge will contain study  drug for 14 doses. Drug cartridges will be provided at each clinic 
visit in sufficient quantity and at appropriate dose levels to ensure uninterrupted administration 
until the next study  visit. Ancillary  supplies including single use needles (31- gauge) and alcohol 
wipes will be provided by  the CRO to the site.
6.3.2 Labeling 
All clinical supplies will be manufactured, tested, labeled and released according to current legal 
and local country  specific regulatory
 requirements and will comply  with Good Manufacturing 
Practices.
A caution statement limiting the investigational product to the clinical trial will be appended as 
regionally  requ ired. For example, in the US the following statement will be appended “For 
clinical trial use only ”, and/or “CAUTION: New Drug -Limited by  Federal (or US) Law to 
Investigational Use” and the statement “Keep out of the reach of children”.
Shire 
SHP634-402 Protocol
CONFIDENTIAL 
Page 33 
27 May 2016
 
   
Additional labels (eg, those used when dispensing marketed product) may , on a case- by-case 
basis, be applied to the investigational product in order to satisfy  local or institutional 
requirements, and must not:
Contradict the clinical study  label
Obscure the clinical study label
Identify  the study  subject by  name
Additional labels may  not be added without the sponsor’s prior full agreement.
Changes to sponsor -supplied packaging prior to dosing may  not occur without full agreement in 
advance b y the sponsor.
6.3.3 Storage
The dual -chamber medication cartridge should be stored between 2 –8 °C. The reconstituted 
medication can be stored for up to 14 days at these conditions. The mixing device and empty  
delivery  pen (ie, unloaded) can be stored at room temperature.
The investigator ha s overall responsibility  for ensuring that investigational product is stored in a 
secure, limited -access location. L imited responsibility  may  be delegated to the pharmacy  or 
member of the stud y team, but this delegation must be documented.
Investigational product must be stored in accordance with labeled storage conditions. 
Temperature monitoring is required at the storage location to ensure that the investigational 
product is maintained within an established temperature range. The investigator is responsib le 
for ensuring that the temperature is monitored throughout the duration of the study and that 
records are maintained; the temperature should be monitored continuously  by using either an in 
house sy stem, a mechanical recording device such as a calibrated chart recorder, or b y manual 
means, such that both minimum and maximum thermometric values over a specific time period 
can be recorded and retrieved as required. Such a device (ie, certified min/max thermometer) 
would require manual resetting upon each rec ording. The sponsor must be notified immediately  
upon discovery  of any  excursion from the established range. Temperature excursions will require 
site investigation as to cause and remediation. The sponsor will determine the ultimate impact of 
excursions on the investigational product and will provide supportive documentation as 
necessary . Under no circumstances should the product be dispensed to subjects until the impact 
has been determined and the product is deemed appropriate for use b y the sponsor.
The s ponsor should be notified immediately  if there are an y changes to the storage area of the 
investigational product that could affect the integrity  of the product(s), eg, fumigation of a 
storage room.
6.3.4 Special Handling
Do not freeze or shake. Do not use rhPTH (1-84) if it has been frozen or shaken.
Shire 
SHP634-402 Protocol
CONFIDENTIAL 
Page 34 
27 May 2016
 
   
6.4 Drug Accountability
The investigator will be provided with sufficient amounts of the investigational product to carry  
out this protocol for the agreed number of subjects. The investigator or designee will 
acknowledge receipt of the investigational product, documenting shipment content and 
condition. Accurate records of all investigational product dispensed, used, returned, and/or 
destroy ed must be maintained as detailed further in this section.
The investigator has ov erall responsibility  for administering/dispensing investigational product. 
Where permissible, tasks may  be delegated to a qualified designee (ie, a pharmacist) who is 
adequatel y trained in the protocol and who works under the direct supervision of the inve stigator. 
This delegation must be documented in the applicable study  delegation of authority  form.
The investigator or his/her designee (as documented by  the investigator in the applicable study  
delegation of authorit y form) will dispense the investigation al product only  to subjects included 
in this study  following the procedures set out in the study  protocol. Each subject will be given 
only the investigational product carry ing his/her treatment assignment. All dispensed study  drug 
will be documented on the eCRFs and/or other investigational product record. The investigator is 
responsible for assuring the retrieval of all stud y supplies from subjects. 
No investigational product stock or returned inventory  from a Shire -sponsored study  may  be 
removed from the site where originall y shipped without prior knowledge and consent b y the 
sponsor. If such transfer is authorized by  the sponsor, all applicable local, state, and national 
laws must be adhered to for the transfer.
At the end of the stud y, or as instructed by  the sponsor, all unused stock, subject returned 
investigational product, and empty /used investigational product packaging are to be sent to a 
nominated contractor on behalf of the sponsor. Investigational products being returned to the 
sponsor’s designated contractors must be counted and verified b y clinical site personnel and the 
sponsor (or designated contract research organization [CRO]). For unused supplies where the 
original supplied tamper -evident feature is verified as intact, the tamper -evident f eature must not 
be broken and the labeled amount is to be documented in lieu of counting. Shipment return 
forms, when used, must be signed prior to shipment from the site. Returned investigational 
products must be packed in a tamper -evident manner to ensur e product integrit y. Contact the 
sponsor for authorization to return an y investigational product prior to shipment. Shipment of all 
returned investigational products must comply  with local, state, and national laws.
Based on entries in the site drug accoun tability  forms, it must be possible to reconcile 
investigational products delivered with those used and returned. All investigational products 
must be accounted for and all discrepancies investigated and documented to the sponsor’s 
satisfaction.
6.5 Subject Co mpliance
Subjects will be instructed to bring their unused investigational product and empty /used 
investigational product packaging to every  visit. Drug accountability  will be assessed at the 
container/packaging level for unused investigational product tha t is contained within the original 
tamper -evident sealed container (eg, bottles, tray s, vials) or at the individual count level for 
Shire 
SHP634-402 Protocol
CONFIDENTIAL 
Page 35 
27 May 2016
 
   
opened containers/packaging. The pharmacist/nominated person will record details on the drug 
accountability  form.
Shire 
SHP634-402 Protocol
CONFIDENTIAL 
Page 36 
27 May 2016
 
   
7. STUDY PROCEDURES
7.1 Study Schedule
See Table 1-1 for a complete list of study  procedures. Site visits will be conducted at 6 -month 
intervals until the end of treatment (EOT) visit at month 24.
A core set of study  procedures, conducted at each site visit, are defined as the following:
Prior/concomitant medications
Vital signs
Serum chemistry  (sodium, potassium, chloride, bicarbonate, blood urea nitrogen, creatinine, 
calcium, phosphate, magnesium, albumin, AL T, AST and AL P).
Should be drawn fasting, prior to administration of calcium or vitamin D supplements 
or rhPTH(1- 84) administration . If in the opinion of the investigator, it is necessary  
for a subject to take calcium and/or active vitamin D supplements prior to traveling 
for blood work, the doses of the pre -draw supplements and their timing with respect 
to the blood draw should be consistent throughout the study  to the greatest extent 
possible.
Urine pregnancy  test
Serum 25- hydroxy vitamin D
Serum 1,25- dihydroxy vitamin D
Bone turnover markers
Serum PTH antibodies (bloo d samples should be drawn prior to dosing)
24-hour urine for calcium, creatinine, phosphate, sodium excretion. Total urinary  volume 
will be recorded. 
HPT multisy mptom questionnaire 
FACT -Cog ( Functional Assessment of Cancer Therap y -Cognitive Function ) assessment 
FACIT (Functional Assessment of Chronic I llness Therapy ) Fatigue Scale
HADS (Hospital Anxiety and Depression Scale) assessment 

AE/SAE monitoring
24-hour urine
Bone mineral density  DXA (dual -energy  x
-ray absorptiometry )
Bone mineral density  HRpQCT (High -resolution peripheral quantitative computerized 
tomograph y)
Dispense/Account for study  drug
7.1.1 Baseline Visit (Visit 1)
All study  procedures outlined in Table 1-1 will be conducted at the baseline visit with t he 
exception of ‘Collection of unused study  drug & injection pen. Additionally , the bone biopsy  is 
an optional procedure, performed once an y time during the stud y, depending on subject history  
and consent.
Shire 
SHP634-402 Protocol
CONFIDENTIAL 
Page 37 
27 May 2016

 
   
7.1.2 Treatment Period 
7.1.2.1 Visit 2, (Month 6)
The core set of study  procedures will be conducted at this visit.
7.1.2.2 Visit 3 (Month 12)
The core set of stud y procedures will be conducted at this visit. I n addition to the core study  
procedures, the following procedures will be performed:
Physical Examination
SF-36 (36-I tem Short Form Health Survey )
7.1.2.3 Visit 4 (Month 18)
The core set of stud y procedures will be conducted at this visit.
7.1.2.4 EOT Visit (Month 24)
All study  procedures outlined in Table 1-1 will be performed at this visit except for the 
following:
Informed consent
Inclusion/exclusion
Medical history  and demography
Serum thy roid stimulating hormone (TSH) 
Serum pregnancy  test
Follicle -stimulating hormone (FSH) level
7.1.3 Additional Care of Subjects after the Study
After the EOT visit or early  termination visit, subjects who will not continue rhPTH[1 -84] 
treatment will have serum calcium and phosphate levels measured 3 to 5 day s after the last dose 
of study  medication. Doses of calcium and active vitamin D supplements will be adjusted by  the 
investigator as appropriate accord ing to guidelines followed in the US package insert. Thereafter, 
the investigator will repeat serum calcium/phosphate monitoring and supplement dose 
adjustments as appropriate to achieve target serum calcium/phosphate concentrations until the 
follow up pho ne call 30 day s ± 7 day s after EOT visit. After the 30- day follow -up phone call, 
further management of hypoparath yroidism will occur as part of the subject’s long -term non -
study  medical care.
7.2 Study Evaluations and Procedures
7.2.1
Demographic and Other Baseline Characteristics
Demographic characteristics will be recorded at the Baseline visit including date of birth, sex, 
and race on the eCRF for each subject. 
Medical history  including etiology  of hypoparathyroidism and duration of hy poparathy roidism 
will be rec orded on the eCRF for each subject. 
Shire 
SHP634-402 Protocol
CONFIDENTIAL 
Page 38 
27 May 2016
 
   
Pre-study  rhPTH(1- 84) treatment will be recorded on the eCRF for each subject.
Pre-study  laboratory  data will be recorded on the eCRF for each subject.
7.2.2 Efficacy
7.2.2.1 Biochemical Evaluations
Biochemical evaluation including s erum calcium, PTH, albumin, phosphate, alkaline 
phosphatase, urine calcium, 25- hydroxyvitamin D, and 1,25- dihydroxyvitamin D will be 
collected at the time points specified in Table 1-1 to assess efficacy  and bone turnover.
7.2.2.2 Hypoparathyroidism Multisymptom Q uestionnaire 
The Hy poparathy roidism Sy mptom Diary  is a 15- item tool describing the subject’s experience 
related to h ypoparath yroidism during the past 24 hours ( Appendix 1 ). 
7.2.2.3 Cognition Tool
The FACT- Cog assessment is a 37 -item tool ( Cella 1997 ). It includes 4 subscales: perceived 
cognitive impairments, impact of perceived cognitive impairments on quality  of life, comments 
from others and perc eived cognitive ability .
7.2.2.4 FACIT Fatigue Scale
FACIT fatigue questionnaire contains 13 fatigue -related questions ( Cella 1997 ). The responses to 
the 13 items on the FACIT fatigue questionnaire are each measured on a 4 -point L ikert scale. 
Thus, the total score ranges from 0 to 52. High scores represent less fatigue.
7.2.2.5 HADS Assessment 
The HADS is a 14- item scale that generates ordinal data ( Zigmond and Snaith 1983). Seven of 
the items relate to anxiety and seven relate to depression. The scale is designed to avoid reliance 
on aspects of conditions that are also common somatic sy mptoms of illness. Each item on the
questionnaire is scored from 0- 3, therefore, a person can score between 0 and 21 for either 
anxiety  or depression. Data returned from the HADS is ordinal.
7.2.2.6 Short Form Health Survey-36
The SF -36 is a validated questionnaire that questions subjects about per ceived phy sical and 
mental health and function. The SF-36 consists of 8 scaled scores, which are the weighted sums 
of the questions in their section. Each scale is directly  transformed into a 0- 100 scale on the 
assumption that each question carries equal w eight; the lower the score the more disability . The 
higher the score the less disability  ie, a score of zero is equivalent to maximum disability  and a 
score of 100 is equivalent to no disability . The eight sections included in the SF -36 assessment 
are vita lity, phy sical functioning, bodily  pain, general health perceptions, phy sical role 
functioning, emotional role functioning, social role functioning, and mental health 
(Ware andSherbourne 1992
).
Shire 
SHP634-402 Protocol
CONFIDENTIAL 
Page 39 
27 May 2016
 
   
7.2.2.7 Bone Mi neral Density
DUAL-ENERGY X-RAY ABSORPTIOMETRY
Dual -energy  X-ray absorptiometry  scans will be performed at Baseline, Month 6, Month 12, 
Month 18, Month 24, and at the EOT visit, if it is greater than 3 months since the previous DXA 
scan. These scans will e valuate bone mineral density  and T -scores of the lumbar spine (ve rtebra 
L1-L4), hip (total and femoral neck), and ⅓ distal radius (arm). 
Please note: DXA will NOT be completed at baseline if subject had a scan performed in the 
previous study .
HIGH-RESOLUTION PERIPHERAL QUANTITATIVE COMPUTERIZED TOMOGRAPHY
High -resoluti on peripheral quantitative computerized tomograph y will be performed at Baseline, 
Month 6, Month 12, Month 18, Month 24, and at the EOT visit. HRpQCT analy ses includes 
Individual Trabecula Segmentation (ITS) anal ysis and finite element modeling.
7.2.2.8 Bone Biopsy
An optional transiliac bone biopsy  will be performed for willing subjects, at the discretion of the 
investigator a maximum of one time during the duration of the study . 
Subjects who agree to have the bone biops y, and have selected to participate in the procedure on 
the Informed Consent Form, will receive two 3 -day courses of tetracy cline with a 12 -day 
window between the first and second course. The bone biopsy  must occur 4 to 6 day s after the 
second tetracy cline course. Subjects should be instructed to a void food and drink for 6 hours 
before the procedure, although small amounts of clear fluids are allowed. 
The incision will be made at the iliac crest, and a bone biopsy needle used to aspirate 1 to 2 
samples of bone from the hip. I nvestigators will follo w their institutional procedures, and use the 
same techniques and equipment if possible.
Subjects should be observed for at least 1 hour postoperativel y and advised to abstain from 
vigorous exercise until 1 week post -procedure. 
7.2.2.9
7.2.3 Safety
7.2.3.1 Adverse Event Collection
At each stud y visit, subjects will be questioned in a general way to ascertain if AEs have 
occurred since the previous visit (ie, “Have you had any health problems since your last visi t?”). 
Adverse events will be collected from the time informed consent is signed. (Please refer to 
Section 8, Adverse and Serious Adverse Events Assessment.)
Shire 
SHP634-402 Protocol
CONFIDENTIAL 
Page 40 
27 May 2016

 
   
7.2.3.2 Clinical Laboratory Evaluations
All clinical laboratory  assay s will be performed according to the laboratory ’s normal procedures. 
Reference ranges are to be supplied by  the laboratory  and will be used to assess the clinical 
laboratory  data for clinical significance and out-of-range pathological changes. The investigator 
should assess out -
of-range clini cal laboratory  values for clinical significance, indicating if the 
value(s) is/are not clinically  significant or clinically  significant. Abnormal clinical laboratory  
values, which are unexpected or not explained by  the subject’s clinical condition, may be 
repeated as soon as possible until confirmed, explained, or resolved, at the discretion of the 
investigator or sponsor.
Lab assessments will be performed during the site visit with the exception of the 24 -hour urine 
collection, which will be collected at a local laboratory . The collection of urine may  occur up to 
2 weeks before the study  visit. 
The following clinical laboratory  assessments will be performed:
CHEMISTRY
Blood samples for serum chemistry will be collected at the time points described in Table 1-1
and will include:
Sodium Phosphate -HCG a,b
Potassium Magnesium FSH a,b
Blood urea nitrogen Total CO 2(Bicarbonate)
Creatinine Albumin
Calcium Aspartate transaminase 
Chloride Alanine transaminase 
Thyroid stimulating hormone (TSH)aAlkaline phosphatase 
25-hydroxy vitamin D 1,25- dihydroxyvitamin D
Creatinine clearance and glomerular filtration rate will be estimated (eGFR) by the laboratory. 
-
HCG=beta -human chorionic gonadotropin; FSH=follicle -stimulating hormone; T3=triiodothyronine; T SH=thyroid stimulating 
hormone.
a Baseline only. 
bFemales only.
HEMATOLOGY
Blood samples for hematology  will be collected at the time points described in Table 1-1 and 
will include:
Hemoglobin Platelet count
Hematocrit White blood cell (WBC) count
Red blood cells (RBC)
Shire 
SHP634-402 Protocol
CONFIDENTIAL 
Page 41 
27 May 2016
 
   
URINALYSIS
A urine sample for urinaly sis will be collected at the time points described in Table 1-1 and will 
include:
pH Blood Nitrites
Glucose Ketones Leukocy te esterase
Protein Bilirubin Specific gravit y
Calcium
Microscopic e xamination will be conducted if protein, leukocyte esterase, and/or blood is/are detected during urinalysis. At a 
minimum the microscopic examination will consist of red blood cells, white blood cells, casts, and bacteria.
24-H OUR URINE
At the beginning o f the study , the investigator should recommend an individualized target dietary  
(non-supplement) calcium intake for each subject to ingest consistently  throughout the study  on 
24-hour urine collection day s. The 24 -hour urine collections should generally  beperformed b y 
the subject within 2 weeks prior to or within 2 days follow a study  visit. These 24
-hour urine 
collections may  be analyzed in a local laboratory . To the greatest extent possible, the same 
laboratory  should anal yze the 24- hour urine collection s throughout the study . Results from the 
last 24-hour urine collection obtained in Columbia protocol AAAE0544 will be used as the 
baseline assessment in this study .
When collecting 24 -hour urine specimens subjects should be instructed to take their currently  
prescribed calcium, vitamin D (both parent and active) and rhPTH(1 -84) doses.
A 24 -hour urine sample will be collected at the time points describe
d in Table 1 -1and will 
include:
Calcium Sodium
Creatinine Total Volume
Phosphate
Magnesium
7.2.3.3 Preg nancy Test
A serum and urine pregnancy  test will be performed on all females of childbearing potential at 
the Baseline Visit (Visit 1 ). Additionally , a urine pregnancy  test will be performed at all 
scheduled stud y visits.
7.2.3.4 PTH Antibodies
A blood sample for PTH antibodies will be collected at the time points described in Table 1-1. 
Blood samples for antibody testing should be collected prior to dosing with PTH[1- 84]. Any  
subject with newly  developed PTH -specific antibodies at the end of treatment visit may  require 
follow up. This will be discussed as necessary  by the PI  and medical monitor on a case -by-case 
basis.
Shire 
SHP634-402 Protocol
CONFIDENTIAL 
Page 42 
27 May 2016
 
   
7.2.3.5 Vital Signs
Vital signs include blood pressure, heart rate, body  temperature, and respiration rate. Blood 
pressure should be determined by  cuff (us ing the same method, the same arm, and in the same 
position throughout the study ). An y clinically  significant deviations from Baseline (Visit 1) vital 
signs which are deemed clinically  significant in the opinion of the investigator areto be recorded 
as an AE.
7.2.3.6 Physical Examination
A phy sical examination including height and weight will be conducted at Baseline, Month 12, 
and Month 24. Abnormalities identified at the Baseline Visit (Visit 1) will be documented in the 
subject’s source documents and on the med ical history  eCRF. Any  clinically  significant 
deviations from Baseline (Visit 1) in physical examination findings which are deemed clinically  
significant in the opinion of the investigator areto be recorded as an AE.
Shire 
SHP634-402 Protocol
CONFIDENTIAL 
Page 43 
27 May 2016
 
   
8. ADVERSE AND SERIOUS ADVERSE EVENTS ASS ESSMENT
8.1 Definition of Adverse Events, Period of Observation, Recording of Adverse Events
An AE is an y untoward medical occurrence in a clinical investigation subject administered a 
pharmaceutical product and that does not necessarily  have a causal relation ship with this 
treatment. An AE can therefore be an y unfavorable and unintended sign (including an abnormal 
laboratory  finding), s ymptom, or disease temporally  associated with the use of a medicinal 
(investigational) product, whether or not related to the medicinal (investigational) product (ICH 
Guidance E2A 1995). 
All AEs are collected from the time the informed consent is signed until the defined follow -up 
period stated in Section 7.1.3 . This includes events occurring during the screening phase of the 
study, regardless of whether or not investigational product is administered. Where possible, a 
diagnosis rather than a list of sy mptoms should be recorded. If a diagnosis has not been made, 
then each s ymptom should be listed individually . All AEs should be c aptured on the appropriate 
AE pages in the eCRF and in source documents. In addition to untoward AEs, unexpected 
benefits outside the investigational product indication should also be captured on the AE eCRF.
All AEs must be followed to closure (the subjec t’s health has returned to his/her baseline status 
or all variables have returned to normal), regardless of whether the subject is still participating in 
the study . Closure indicates that an outcome is reached, stabilization achieved (the investigator 
does not expect any  further improvement or worsening of the event), or the event is otherwise 
explained. When appropriate, medical tests and examinations are performed so that resolution of 
event(s) can be documented.
8.1.1 Severity Categorization
The severit y of AE s must be recorded during the course of the event including the start and stop 
dates for each change in severity. An event that changes in severity should be captured as a new 
event. Worsening of pre -treatment events, after initiation of investigational pr oduct, must be 
recorded as new AEs (for example, if a subject experiences mild intermittent dy spepsia prior to 
dosing of investigational product, but the dy spepsia becomes severe and more frequent after first 
dose of investigational product has been admini stered, a new AE of severe dy spepsia [with the 
appropriate date of onset] is recorded on the appropriate eCRF).
The medical assessment of severit y is determined by using the following definitions:
Mild : A ty pe of AE that is usually  transient and may  requir e only  minimal treatment or 
therapeutic intervention. The event does not generally  interfere with usual activities of daily  
living.
Moderate : A type of AE that is usually  alleviated with specific therapeutic intervention. The 
event interferes with usual ac tivities of daily  living, causing discomfort but poses no significant 
or permanent risk of harm to the research subject.
Severe : A type of AE that interrupts usual activities of daily living, or significantly affects 
clinical status, or may  require intensi ve therapeutic intervention.
Shire 
SHP634-402 Protocol
CONFIDENTIAL 
Page 44 
27 May 2016
 
   
8.1.2 Relationship Categorization
A phy sician/investigator must assess the relationship to investigational product for each AE. The 
investigator should decide whether, in his or her medical judgment, there is a reasonable 
possibility that the event may  have been caused by the investigational product. If there is no 
valid reason for suggesting a relationship, then the AE should be classified as “not related”. 
Otherwise, if there is an y valid reason, even if undetermined or untested, fo r suspecting a 
possible cause -and-effect relationship between the investigational product and the occurrence of 
the AE, then the AE should be considered “related”. The causality  assessment must be 
documented in the source document.
The following additional guidance may  be helpful:
Term Relationship Definition
RelatedThe temporal relationship between the event and the administration of the 
investigational product is compelling and/or follows a known or suspected response 
pattern to that product, and the ev ent cannot be explained by the subject’s medical 
condition, other therapies, or accident.
Not RelatedThe event can be readily explained by other factors such as the subject’s underlying 
medical condition, concomitant therapy, or accident and no plausi ble temporal or 
biologic relationship exists between the investigational product and the event.
8.1.3 Outcome Categorization
The outcome of AEs must be recorded during the course of the stud y on the eCRF. Outcomes are 
as follows:
Fatal
Not Recovered/Not Resolv ed
Recovered/Resolved
Recovered/Resolved With Sequelae 
Recovering/Resolving
Unknown
8.1.4 Symptoms of the Disease Under Study
Symptoms of the disease under study  should not be classed as AEs as long as they  are within the 
normal day -to-day fluctuation or expect ed progression of the disease and are part of the efficacy  
data to be collected in the study; however, significant worsening of the s ymptoms should be 
recorded as an AE.
8.1.5 Clinical Laboratory and Other Safety Evaluations
A change in the value of a clinical l aboratory  or vital signs assessment can represent an AE if the 
change is clinicall y relevant or if, during treatment with the investigational product, a shift of a 
parameter is observed from a normal value to an abnormal value, or a further worsening of an
alread y abnormal value. When evaluating such changes, the extent of deviation from the 
reference range, the duration until return to the reference range, either while continuing treatment 
Shire 
SHP634-402 Protocol
CONFIDENTIAL 
Page 45 
27 May 2016
 
   
or after the end of treatment with the investigational product, and the range of variation of the 
respective parameter within its reference range, must be taken into consideration.
If, at the end of the treatment phase, there are abnormal clinical laboratory  or vital signs values 
which were not present at the pre- treatmen t value observed closest to the start of study  treatment, 
further investigations should be performed until the values return to within the reference range or 
until a plausible explanation (ie, concomitant disease) is found for the abnormal values.
The inve stigator should decide, based on the above criteria and the clinical condition of a 
subject, whether a change in a clinical laboratory  or vital signs parameter is clinically  significant 
and therefore represents an AE.
8.1.6 Pregnancy
All pregnancies are to be reported from the time informed consent is signed until the defined 
follow -up period stated in Section 7.1.3.
Any report of pregnancy  for any  female study  participant must be reported within 24 hours to the 
Shire Global Pharmacovigilance and Risk Management Department using the Shire 
Investigational and Marketed Products Pregnancy  Report Form. A copy  of the Shire 
Investigational and Marketed Products Pregnancy  Report Form (and any  applicable follow -
up 
reports) must also be sent to the CRO/Shire Medical Monito r using the details specified in the 
emergency  contact information section of the protocol. The pregnant female study  participant 
must be withdrawn from the study .
Every  effort should be made to gather information regarding the pregnancy  outcome and 
condit ion of the infant. It is the responsibility  of the investigator to obtain this information within 
30 calendar day s after the initial notification and approximately  30 calendar day s postpartum.
Pregnancy  complications such as spontaneous abortion/miscarriag e or congenital abnormality  
are considered SAEs and must be reported using the Shire Clinical Study  Serious Adverse Event 
and Non -serious AEs Required by  the Protocol Form. Note: An elective abortion is not 
considered an SAE.
In addition to the above, if t he investigator determines that the pregnancy  meets serious criteria, 
it must be reported as an SAE using the Shire Clinical Study  Serious Adverse Event and Non-
serious AEs Required b y the Protocol Form as well as the Shire Investigational and Marketed 
Products Pregnancy  Report Form. The test date of the first positive serum/urine -HCG (beta -
human chorionic gonadotropin) test or ultrasound result will determine the pregnancy onset date.
8.1.7 Abuse, Misuse, Overdose, and Medication Error
Abuse, misuse, overdose, or medication error (as defined below) must be reported to the sponsor 
according to the SAE reporting procedure whether or not they  result in an AE/SAE as described 
in Section 8.2. Note: The 24 -hour reporting requirement for SAEs does not apply  to reports of 
abuse, misuse, overdose, or medication errors unless these resu
lt in an SAE. 
The categories below are not mutually  exclusive; the event can meet more than 1 category .
Shire 
SHP634-402 Protocol
CONFIDENTIAL 
Page 46 
27 May 2016
 
   
Abuse –Persistent or sporadic intentional intake of investigational product when used for a non-
medical purpose (eg, to alter one’s state of consciousness or get high) in a manner that may  be 
detrimental to the individual and/or societ y
Misuse – Intentional use of investigational product other than as directed or indicated at any  dose 
(Note: this includes a situation where the investigational product is not used as directed at the 
dose prescribed b y the protocol)
Overdose –Intentional or unintentional intake of a dose of an investigational product exceeding 
a pre -specified total dail y dose of 250 µg of the product.
Medication Error – An error made in prescribing, dispensing, administration, and/or use of an 
investigational product. For studies, medication errors are reportable to the sponsor only as 
defined below.
Cases of subjects missing doses of the investigational product are not considered reportable 
as medication errors.
Medication errors should be collected/reported for all products under investigation.
The administration and/or use of an expired investigational product should be co nsidered as a 
reportable medication error.
Acute accidental overdosage of rhPTH(1
-84) can result in transient hy percalcemia and 
hypercalciuria. Treatment of suspected overdose should include temporary  discontinuation of 
rhPTH(1 -84), monitoring of serum cal cium, and implementation of appropriate, supportive 
measures such as h ydration. Due to the relativel y short duration of the pharmacological activit y 
of rhPTH(1- 84), further measures should not be necessary .
8.2 Serious Adverse Event Procedures
8.2.1 Reference Safety Information
The reference for safet y information for this study is the investigators brochure ,which the 
sponsor has provided under separate cover to all investigators. 
8.2.2 Reporting Procedures
All initial and follow -up SAE reports must be reported by  the in vestigator to the Shire Global 
Pharmacovigilance and Risk Management Department and the Shire Medical Monitor within 24 
hours of the first awareness of the event. Note: The 24-hour reporting requirement for SAEs does 
not apply  to reports of abuse, misuse, overdose, or medication errors (see Section 8.1.7) unless 
they result in an SAE. 
The investigator must complete, sign, and date the Shire Clinical Study  Serious Adverse Event 
and Non -serious AEs Required by  the Protocol Form and verify  the accuracy  of the information 
recorded on the form with the corresponding source documents (Note: Source documents are not 
to be sent unless requested) and fax or e mail the form to the Shire Global Pharmacovigilance 
and Risk Management Department. A cop y of the Shire Clin ical Study  Serious Adverse Event 
and Non -serious AEs Required by
 the Protocol Form (and any  applicable follow -up reports) 
Shire 
SHP634-402 Protocol
CONFIDENTIAL 
Page 47 
27 May 2016
 
   
must also be sent to the Shire Medical Monitor using the details specified in the emergency  
contact information section of the protoco l.
8.2.3 Serious Adverse Event Definition
A Serious Adverse Event (SAE) is an y untoward medical occurrence (whether considered to be 
related to investigational product or not) that at any dose:
Results in death
Is life -threatening. Note: The term “life-threatening” in the definition of “serious” refers to an 
event in which the subject was at risk of death at the time of the event; it does not refer to an 
event that h ypotheticall y might have caused death if it was more severe.
Requires inpatient hospitalization or prolongation of existing hospitalization. Note: 
Hospitalizations, which are the result of elective or previousl y scheduled surgery for pre -
existing conditions, which have not worsened after initiation of treatment, should not be 
classified as SAEs. For ex ample, an admission for a previousl y scheduled ventral hernia 
repair would not be classified as an SAE; however, complication(s) resulting from a 
hospitalization for an elective or previousl y scheduled surgery  that meet(s) serious criteria 
must be reported as SAE(s).
Results in persistent or significant disability /incapacity
Is a congenital abnormality /birth defect
Is an important medical event. Note: I mportant medical events that may  not result in death, 
be life -threatening, or require hospitalization may  be considered an SAE when, based upon 
appropriate medical judgment, they  may  jeopardize the subject and may  require medical or 
surgical intervention to prevent 1 of the outcomes listed in this definition. Examples of such 
medical events include allergic br onchospasm requiring intensive treatment in an emergency  
room or at home; blood dyscrasias or convulsions that do not result in inpatient 
hospitalization; or the development of drug dependency  or drug abuse. 
8.2.4 Serious Adverse Event Collection Time Frame
AllSAEs (regardless of relationship to study ) are collected from the time the subject signs the 
informed consent until the defined follow- up period stated in Section 7.1.3, and must be reported 
to the Shire Global Pharmacovigilance and Risk Management Depart ment and the Shire Medical 
Monitor within 24 hours of the first awareness of the event. 
In addition, any
 SAE(s) considered “related” to the investigational product and discovered by  the 
investigator at an y interval after the study has completed must be re ported to the Shire Global 
Pharmacovigilance and Risk Management Department within 24 hours of the first awareness of 
the event.
8.2.5 Serious Adverse Event Onset and Resolution Dates
The onset date of the SAE is defined as the date the event meets serious crite ria. The resolution 
date is the date the event no longer meets serious criteria, the date the s ymptoms resolve, or the 
event is considered chronic. I n the case of hospitalizations, the hospital admission and discharge 
dates are considered the onset and res olution dates, respectivel y.
Shire 
SHP634-402 Protocol
CONFIDENTIAL 
Page 48 
27 May 2016
 
   
In addition, any  signs or sy mptoms experienced by  the subject after signing the ICF, or leading 
up to the onset date of the SAE, or following the resolution date of the SAE, must be recorded as 
an AE, if appropriate.
8.2.6 Fatal Outc ome
Any SAE that results in the subject’s death (ie, the SAE was noted as the primary  cause of death) 
must have fatal checked as an outcome with the date of death recorded as the resolution date. For 
all other events ongoing at the time of death that did n ot contribute to the subject’s death, the 
outcome should be considered not resolved, without a resolution date recorded.
For an y SAE that results in the subject’s death or any ongoing events at the time of death, unless 
another investigational product acti on was previously  taken (eg, drug interrupted, reduced, 
withdrawn), the action taken with the investigational product should be recorded as “dose not 
changed” or “not applicable” (if the subject never received investigational product). The 
investigational product action of “withdrawn” should not be selected solel y as a result of the 
subject’s death.
8.2.7 Regulatory Agency, Institutional Review Board, Ethics Committee, and Site 
Reporting
The sponsor and/or CRO is responsible for notifying the relevant regulatory  authorities/US 
central Institutional Review Boards (I RBs) of related, unexpected SAEs.
In addition, the sponsor and/or CRO is responsible for notify ing active sites of all related, 
unexpected SAEs occurring during all interventional studies across the SHP6 34-402 program. 
The investigator is responsible for notify ing the local IRB, local Ethics Committee (EC), or the 
relevant local regulatory  authority  of all SAEs that occur at his or her site as required.
Shire 
SHP634-402 Protocol
CONFIDENTIAL 
Page 49 
27 May 2016
 
   
9. DATA MANAGEMENT AND STATISTICAL METHODS
9.1 Data Collec tion
The investigators’ authorized site personnel must enter the information required by  the protocol 
on the eCRF. A stud y monitor will visit each site in accordance with the monitoring plan and 
review the eCRF data against the source data for completeness and accuracy . Discrepancies 
between source data and data entered on the eCRF will be addressed b y qualified site personnel. 
When a data discrepancy warrants correction, the correction will be made by authorized site 
personnel. Data collection procedures w ill be discussed with the site at the site initiation visit 
and/or at the investigator’s meeting. It is expected that site personnel will complete the eCRF 
entry  within approximately  3 business day s of the subject’s visit.
9.2 Clinical Data Management
Data are to be entered into a clinical database as specified in the study  data management plan. 
Quality  control and data validation procedures are applied to ensure the validity  and accuracy  of 
the clinical database.
Data are to be reviewed and checked for omissio ns, errors, and values requiring further 
clarification using computerized and manual procedures. Data queries requiring clarification are 
to be communicated to the site for resolution. Only authorized personnel will make corrections to 
the clinical databas e, and all corrections are documented in an auditable manner.
9.3 Data Handling Considerations
Not Applicable.
9.4 Statistical Analysis Process
The statistical anal ysis plan (SAP) will provide the statistical methods and definitions for the 
analysis of the efficac y and safet y data, as well as describe the approaches to be taken for 
summarizing other study  information such as subject disposition, demographics and baseline 
characteristics, stud y treatment exposure, and prior and concomitant medications. The SAP will 
also include a description of how missing, unused and spurious data will be addressed.
All statistical analy
ses will be performed using Statistical Analy sis Sy stem (SAS) (SAS 
Institute, Cary , NC, USA) version 9.3 or higher. 
9.5 Planned Interim Analysis, Adap tive Design, and Data Monitoring Committee
A retrospective anal ysis of historical data captured from the medical records of subjects (eg, 
since the start of rhPTH(1 -84) treatment) will be conducted. Data collected will include but is not 
limited to, medica l history and clinical laboratory  data. There are no formal hy potheses testing 
for the retrospective analysis. Descriptive statistics will be calculated for quantitative safet y data 
as well as for the difference from the pre -rhPTH(1 -84) treatment baseline, if applicable.
Shire 
SHP634-402 Protocol
CONFIDENTIAL 
Page 50 
27 May 2016
 
   
9.6 Sample Size Calculation and Power Considerations
No formal sample size calculation was performed.
9.7 Study Population
The Safety Population will be used for all analysis in this study  and consists of all subjects who 
receive at least 1 dose of rhPTH(1 -84). 
9.8 Efficacy Analyses
9.8.1 Primary Efficacy Endpoint
Albumin -corrected serum calcium over time
The primary  efficacy  endpoint is defined as the albumin -corrected serum calcium concentration 
over time at each stud y visit (ie, every  6 months). The Basel ine serum calcium concentration is 
the final measurement taken prior to initiating treatment.
The change and percentage changes from baseline will be summarized at each visit. No formal 
statistical test will be conducted. 95% confidence intervals (CI) will be provided as appropriate.
9.8.2 Secondary Efficacy Endpoints
The secondary  endpoints are defined as follows:
Urinary  calcium and serum phosphate over time
Calcium and active vitamin D supplement doses over time
HPT Disease -related s ymptoms (Multisy mptom quest ionnaire), FACT -Cog assessment, 
FACIT (Fatigue Scale [Version 4]), and HADS
Health-related quality-of- life measured with SF -36 survey  over time
Bone turnover (markers), architecture, and histology  (biops y) over time
For continuous variables, the change and percent changes from baseline will be summarized 
using descriptive statistics including number of subjects, mean, median, standard deviation, 
maximum, and minimum. The same anal ysis using core study  (AAAE0544) baseline will be 
performed. CIs of 95% will b e provided as appropriate. For categorical variables, statistical 
summaries will include number of subjects and percentages. 
9.8.3 Exploratory Efficacy Endpoints

Exploratory  endpoints will be summarized with descriptive statistics or frequency  counts and 
percentage as appropriate.
Shire 
SHP634-402 Protocol
CONFIDENTIAL 
Page 51 
27 May 2016

 
   
9.9 Safety Analyses
Safety  anal ysis will be conducted on the safet y population as defined in Section 9.7. The 
following safet
y variables constitute the safety endpoints measured in this study:
AEs including SAEs
Symptoms of hy poparathy roidism
Vital signs including body temperature (°C/°F), heat rate (beats per minute), respiratory  rate,
and blood pressure (s ystolic and diastolic [mmHg])
Estimated Glomerular Filtration Rate (eGFR) and creatinine clearance
Measurement of PTH antibody
Laboratory  safet y data (eg, clinical chemistry, hematology and urinalysis)
Adverse events will be coded usi ng the Medical Dictionary  for Regulatory  Activities 
(MedDRA). The number of events, incidence, and percentage of treatment -emergent adverse 
events (TEAEs) will be calculated overall, b y system organ class (SOC), by  preferred term, and 
by treatment group. T EAEs will be further summarized by  severity  and relationship to 
investigational product. AEs related to investigational product, AEs leading to withdrawal, 
SAEs, and deaths will be similarly  summarized/listed. Clinical laboratory  tests and vital signs 
findings will be summarized by  treatment group and visit. Potentially  clinically  important 
findings will also be summarized or listed.
9.10 Other Analyses
Historical laboratory  and medical history  data on each subject will be summarized. 
Any available historical d ata will be collected in the following order of priority : 
Priority 1:
Serum calcium and albumin
Urine calcium excretion (to include 24 hour urine collections or estimates of 24 hour 
excretion based on 2 hour collections)
Serum phosphate
Serum creatinine•S F-36 results
Priority 2:
Calcium and Vitamin D supplement doses
Serum magnesium
DXA bone densit y results
HRpQCT results•24 hour urine creatinine, volume
Priority 3:
Shire 
SHP634-402 Protocol
CONFIDENTIAL 
Page 52 
27 May 2016
 
   
25-OH Vitamin D and 1,25 -dihydoxy -Vitamin D levels
Medical History /
Bone Turnover Markers
Vital signs (bod y temperature, heat rate, respiratory rate, and blood pressure (s ystolic and 
diastolic)
Electrocardiogram (ECG) parameters (atrial and ventricular rates and PR, QRS, and QTc 
intervals)
Laboratory  safet y data (eg, clinical chemist ry, hematology , and urinaly sis)
24 hour urine phosphate, sodium
Bone histology  and histomorphometry  results
Descriptive statistics will used to evaluate the historical data, if applicable.
9.10.1 Health -related Quality of Life Analyses
SF-36 endpoints will be measured. For each endpoint, the change in Quality  of Life score from 
baseline to the end of treatment will be measured relative to those measured just prior to 
beginning rhPTH(1 -84) treatment and relative to Visit 1 in this study .
Shire 
SHP634-402 Protocol
CONFIDENTIAL 
Page 53 
27 May 2016

 
   
10. SPONSOR’S AND I NVESTIGATOR’S RESPONSIBILITIES
This study  is conducted in accordance with current applicable regulations, International 
Conference on Harmonisation (I CH), European Union (EU) Directive 2001/20/EC and its 
updates, and local ethical and legal requirements. 
The name and address of each third part y vendor (ie, CRO) used in this study will be maintained 
in the investigator’s and sponsor’s files, as appropriate.
10.1 Sponsor’s Responsibilities
10.1.1 Good Clinical Practice Compliance
The study  sponsor and any  third party  towhom aspects of the study  management or monitoring 
have been delegated will undertake their assigned roles for this study  in compliance with all 
applicable industry  regulations, I CH GCP Guideline E6 (1996), European Union (EU) Directive 
2001/20/EC, as wel l as all applicable national and local laws and regulations.
Visits to sites are conducted by  representatives of the study  sponsor and/or the company  
organizing/managing the research on behalf of the sponsor to inspect study  data, subjects’ 
medical records, and eCRFs in accordance with current Good Clinical Practice (GCP) and the 
respective local and (inter)national government regulations and guidelines. Records and data 
may additionally  be reviewed by  auditors or b y regulatory  authorities.
The sponsor ensures that local regulatory  authority requirements are met before the start of the 
study . The sponsor (or a nominated designee) is responsible for the preparation, submission, and 
confirmation of receipt of an y regulatory  authority  approvals required prior t o release of 
investigational product for shipment to the site.
10.1.2 Public Posting of Study Information
The sponsor is responsible for posting appropriate study  information on applicable websites. 
Information included in clinical study  registries may  include pa rticipating investigators’ names 
and contact information.
10.1.3 Submission of Summary of Clinical Study Report to Competent Authorities 
of Member States Concerned and Ethics Committees
The sponsor will provide a summary  of the clinical study  report (CSR) to the competent 
authority  of the member state(s) concerned as required by  regulatory  requirement(s) and to 
comply  with the Community  guideline on GCP. This requirement will be fulfilled within 6 
months of the end of the study  completion date for pediatric studie s and within 1 y ear for non -
pediatric studies as per guidance.
10.1.4 Study Suspension, Termination, and Completion
The sponsor may  suspend or terminate the study , or part of the study , at any  time for any  reason. 
If the stud y is suspended or terminated, the spon sor will ensure that applicable sites, regulatory  
agencies and IRBs/ECs are notified as appropriate. Additionally , the discontinuation of a 
Shire 
SHP634-402 Protocol
CONFIDENTIAL 
Page 54 
27 May 2016
 
   
registered clinical study  which has been posted to a designated public website will be updated 
accordingl y.
10.2 Investigator’s Responsibilities
10.2.1 Good Clinical Practice Compliance
The investigator must undertake to perform the study  in accordance with ICH GCP Guideline E6 
(1996), EU Directive 2001/20/EC, and applicable regulatory  requirements and guidelines.
It is the investi gator’s responsibility  to ensure that adequate time and appropriately  trained 
resources are available at the site prior to commitment to participate in this study . The 
investigator should also be able to estimate or demonstrate a potential for recruiting t he required 
number of suitable subjects within the agreed recruitment period.
The investigator will maintain a list of appropriately  qualified persons to whom the investigator 
has delegated significant study -related tasks, and shall, upon request of the sponsor, provide 
documented evidence of any  licenses and certifications necessary  to demonstrate such 
qualification. Curriculum vitae for investigators and sub investigators are provided to the study 
sponsor (or designee) before starting the study .
If a pote ntial research subject has a primary  care phy sician, the investigator should, with the 
subject’s consent, inform them of the subject’s participation in the study .
A coordinating principal investigator is appointed to review the final CSR for multicenter 
studies. Agreement with the final CSR is documented by  the signed and dated signature of the 
principal investigator (single -site study ) or coordinating principal investigator (multicenter 
study ), in compliance with Directive 2001/83/EC as amended b y Directive 2003/63/EC and I CH 
Guidance E3 (1995).
10.2.2 Protocol Adherence and Investigator Agreement
The investigator and an y co-investigators must adhere to the protocol as detailed in this 
document. The investigator is responsible for enrolling only  those subjects who have met 
protocol eligibility  criteria. Investigators are required to sign an investigator agreement to 
confirm acceptance and willingness to comply  with the study  protocol.
If the investigator suspends or terminates the study  at their site, the investiga tor will promptly  
inform the sponsor and the I RB/EC and provide them with a detailed written explanation. The 
investigator will also return all investigational product, containers, and other study materials to 
the sponsor. Upon study completion, the invest igator will provide the sponsor, I RB/EC, and 
regulatory  agency  with final reports and summaries as required by  (inter)national regulations.
Communication with local I RBs/ECs, to ensure accurate and timel y information is provided at 
all phases during the study , may  be done by  the sponsor, applicable CRO, investigator, or for 
multicenter studies, the coordinating principal investigator according to national provisions and 
will be documented in the investigator agreement.
Shire 
SHP634-402 Protocol
CONFIDENTIAL 
Page 55 
27 May 2016
 
   
10.2.3 Documentation and Retention of Records
10.2.3.1 Case Report Forms
Case report forms (CRFs) are supplied b y the CRO and should be handled in accordance with 
instructions from the sponsor.
The investigator is responsible for maintaining adequate and accurate medical records from 
which accurate informatio n is recorded onto eCRFs, which have been designed to record all 
observations and other data pertinent to the clinical investigation. CRFs must be completed b y 
the investigator or designee as stated in the site delegation log.
All data sent to the sponsor must be endorsed b y the investigator.
The clinical research associate (CRA)/study  monitor will verify  the contents against the source 
data per the monitoring plan. If the data are unclear or contradictory , queries will be sent for 
corrections or verification of data.
10.2.3.2 Recording, Access, and Retention of Source Data and Study Documents
Original source data to be reviewed during this study  will include, but are not limited to: 
subject’s medical file, original clinical laboratory  reports, and histology  and path ology  reports.
All key  data must be recorded in the subject’s medical records.
The investigator must permit authorized representatives of the sponsor, the respective national, 
local, or foreign regulatory  authorities, the IRB/EC, and auditors to inspect fa cilities and to have 
direct access to original source records relevant to this study , regardless of media.
The CRA/study  monitor (and auditors, IRB/EC or regulatory  inspectors) may  check the eCRF 
entries against the source documents. The consent form inclu des a statement by  which the 
subject agrees to the monitor/auditor from the sponsor or its representatives, national or local 
regulatory  authorities, or the I RB/EC, having access to source data (eg, subject’s medical file, 
appointment books, original labor atory  reports, X -rays etc).
These records must be made available within reasonable times for inspection and duplication, if 
required, b y a properly  authorized representative of any  regulatory  agency  (eg, the US Food and 
Drug Administration (FDA), European Medicines Agency  (EMA), UK Medicines and 
Healthcare Products Regulatory  Agency ) or an auditor.
Essential documents must be maintained according to ICH GCP requirements and may  not be 
destroy ed without written permission from the sponsor.
10.2.3.3 Audit/Inspection
To ensure compliance with relevant regulations, data collected for and generated b y this study 
must be available for inspection upon request b y representatives of, for example, the US FDA (as 
well as other US national and local regulatory  authorities), the EMA, the Medicines and 
Healthcare Products Regulatory  Agency , other regulatory  authorities, the sponsor or its 
representatives, and the IRB/EC for each site.
Shire 
SHP634-402 Protocol
CONFIDENTIAL 
Page 56 
27 May 2016
 
   
10.2.3.4 Financial Disclosure
The investigator is required to disclose an y financial arrangement during the study  and for 1 y ear 
after, whereb y the outcome of the study  could be influenced by  the value of the compensation for 
conducting the study , or other pay ments the investigator received from the sponsor. The 
following information is collected: an y significa nt pay ments from the sponsor or subsidiaries 
such as a grant to fund ongoing research, compensation in the form of equipment, retainer for 
ongoing consultation or honoraria; an y proprietary interest in investigational product; an y 
significant equity  intere st in the sponsor or subsidiaries as defined in 21 CFR 54 2(b) (1998).
10.3 Ethical Considerations
10.3.1 Informed Consent
It is the responsibility  of the investigator to obtain written informed consent from all study  
subjects prior to an y study -related procedures inc luding screening assessments. All consent 
documentation must be in accordance with applicable regulations and ICH GCP. The I nformed 
Consent procedure has been modified to allow remote consenting of subjects for this phase 4 
study . A member of the study  team will send the Informed Consent document by  mail or e -mail 
to the subject and discuss the document by  telephone. Each subject or the subject’s legally-
authorized representative, as applicable, is requested to sign and date the subject informed 
consent for m or a certified translation if applicable, after the subject has received and read (or 
been read) the written subject information and received an explanation of what the study  
involves, including but not limited to: the objectives, potential benefits and risk, inconveniences, 
and the subject’s rights and responsibilities. The subject will return their signed informed consent 
document to the site. Upon receipt of the subject’s consent, the authorized consenter who 
performed the remote informed consent proce dure will phy sicall y sign and date the consent 
document as well. A copy of the informed consent documentation (ie, a complete set of subject 
information sheets and fully  executed signature pages) must be given to the subject or the 
subject’s legall y-author ized representative, as applicable. This document may  require translation 
into the local language. Signed consent forms must remain in each subject’s study  file and must 
be available for verification at an y time.
The principal investigator provides the spo nsor with a copy  of the consent form which was 
reviewed b y the IRB/EC and which received their favorable opinion/approval. A cop y of the 
IRB/EC’s written favorable opinion/approval of these documents must be provided to the 
sponsor, prior to the start of t he study  unless it is agreed to and documented (abiding by  
regulatory  guidelines and national provisions) prior to study  start that another part y (ie, sponsor 
or coordinating principal investigator) is responsible for this action. Additionally, if the IRB/EC 
requires modification of the sample subject information and consent document provided b y the 
sponsor, the documentation supporting this requirement must be provided to the sponsor.
10.3.2 Institutional Review Board or Ethics Committee
It is the responsibility  of the investigator to submit this protocol, the informed consent document 
(approved b y the sponsor or their designee), relevant supporting information and all ty pes of 
subject recruitment information to the I RB/EC for review, and all must be approved prio
r to site 
initiation.
Shire 
SHP634-402 Protocol
CONFIDENTIAL 
Page 57 
27 May 2016
 
   
Responsibility  for coordinating with IRBs/ECs is defined in the investigator agreement.
Prior to implementing changes in the study , the sponsor and the IRB/EC must approve any  
revisions of all informed consent documents and amendments to the protocol unless there is a 
subject safet y issue.
Investigational product supplies will not be released until the sponsor/CRO has received written 
IRB/EC approval of and copies of revised documents.
The investigator is responsible for keeping the IRB/EC apprised of the progress of the stud y and 
of an y changes made to the protocol, but in an y case at least once a year; for sites within the EU, 
this can be done b y the sponsor, the investigator or for multicenter studies the coordinating 
principal investigator, according to national provisions. The investigator must also keep the local 
IRB/EC informed of an y serious and significant AEs.
10.4 Privacy and Confidentiality
All US-based sites and laboratories or entities providing support for this study , must, whe re 
applicable, compl y with the Health Insurance Portability and Accountability Act (HIPAA) of 
1996. A site that is not a covered entity  as defined by  HIPAA must provide documentation of 
this fact to the CRO/sponsor.
The confidentialit y of records that may be able to identify  subjects will be protected in 
accordance with applicable laws, regulations, and guidelines.
After subjects have consented to take part in the study , the sponsor and/or its representatives 
reviews their medical records and data collected during the study . These records and data may , in 
addition, be reviewed b y others including the following: independent auditors who validate the 
data on behalf of the sponsor; third parties with whom the sponsor may  develop, register, or 
market rhPTH(1 -84); national or local regulatory  authorities; and the IRB(s)/EC(s) which gave 
approval for the study  to proceed. The sponsor and/or its representatives accessing the records 
and data will take all reasonable precautions in accordance with applicable laws, re gulations, and 
guidelines to maintain the confidentialit y of subjects’ identities.
Subjects are assigned a unique identify ing number; however, their initials and date of birth may  
also be collected and used to assist the sponsor to verify  the accuracy  of the data (ie, to confirm 
that laboratory  results have been assigned to the correct subject). 
The results of studies –containing subjects’ unique identify ing number, relevant medical 
records, and possibly  initials and dates of birth –will be recorded. The y may be transferred to, 
and used in, other countries which may  not afford the same level of protection that applies within 
the countries where this study  is conducted. The purpose of an y such transfer would include: to 
support regulatory  submissions, to c onduct new data anal yses to publish or present the study  
results, or to answer questions asked by  regulatory or health authorities.
Shire 
SHP634-402 Protocol
CONFIDENTIAL 
Page 58 
27 May 2016
 
   
10.5 Study Results / Publication Policy
Shire will endeavor to publish the results of all qualify ing, applicable, and covered stu dies 
according to external guidelines in a timely  manner regardless of whether the outcomes are 
perceived as positive, neutral, or negative. Additionally , Shire adheres to external guidelines (eg, 
Good Publication Practices 2) when forming a publication steering committee, which is done for 
large, multicenter Phase 2 -4 and certain other studies as determined b y Shire. The purpose of the 
publication steering committee is to act as a non
-commercial body  that advises or decides on 
dissemination of scientific s tudy data in accordance with the scope of this policy .
All publications relating to Shire products or projects must undergo appropriate technical and 
intellectual propert y review, with Shire agreement to publish prior to release of information. The 
review is aimed at protecting the sponsor’s proprietary  information existing either at the 
commencement of the study  or generated during the study . To the extent permitted by  the 
publisher and cop yright law, the principal investigator will own (or share with othe r authors) the 
copy right on his/her publications. To the extent that the principal investigator has such sole, joint 
or shared rights, the principal investigator grants the sponsor a perpetual, irrevocable, ro yalty 
free license to make and distribute copie s of such publications.
The term “publication” refers to an y public disclosure including original research articles, review 
articles, oral presentations, abstracts and posters at medical congresses, journal supplements, 
letters to the editor, invited lectu res, opinion pieces, book chapters, electronic postings on 
medical/scientific websites, or other disclosure of the study  results, in printed, electronic, oral or 
other form.
Subject to the terms of the paragraph below, the investigator shall have the right to publish the 
study  results, and any  background information provided by  the sponsor that is necessary  to 
include in an y publication of study results, or necessary for other scholars to verify such stud y 
results. Notwithstanding the fore going, no publication that incorporates the sponsor’s 
confidential information shall be submitted for publication without the sponsor’s prior written 
agreement to publish, and shall be given to the sponsor for review at least 60 days prior to 
submission fo r publication. If requested in writing by  Shire, the institution and principal 
investigator shall withhold submission of such publication for up to an additional 60 day s to 
allow for filing of a patent application.
If the stud y is part of a multicenter stu dy, the first publication of the study  results shall be made 
by the sponsor in conjunction with the sponsor’s presentation of a joint, multicenter publication 
of the compiled and analy zed study  results. If such a multicenter publication is not submitted to a 
journal for publication by  the sponsor within an 18-month period after conclusion, abandonment, 
or termination of the study at all sites, or after the sponsor confirms there shall be no multicenter 
study  publication of the study  results, an investigator may individuall y publish the study results 
from the specific site in accordance with this section. The investigator must; however, 
acknowledge in the publication the limitations of the single site data being presented.
Unless otherwise required by  the journal in which the publication appears, or the forum in which 
it is made, authorship will comply  with the International Committee of Medical Journal Editors 
Shire 
SHP634-402 Protocol
CONFIDENTIAL 
Page 59 
27 May 2016
 
   
(ICMJE) current standards. Participation as an investigator does not confer any  rights to 
authorship of publications.
Shire 
SHP634-402 Protocol
CONFIDENTIAL 
Page 60 
27 May 2016
 
   
11. REFERENCES
Arlt, W., Fremerey , C., Callies, F., Reincke, M., Schneider, P., Timmermann, W. & Allolio, B. 
2002. Well -being, mood and calcium homeostasis in patients with hy poparathy roidism 
receiving standard treatment w ith calcium and vitamin D. Eur J Endocrinol, 146, 215-22.
Avioli, L . V. 1974. The therapeutic approach to hy poparathy roidism. Am J Med, 57,34-42.
Behaghel, A. & Donal, E. 2011. Hy pocalcaemia -induced transient dilated cardiom yopath y in 
elderl y: a case repo rt. Eur J Echocardiogr, 12,E38.
Blaine, J., Chonchol, M. & Levi, M. 2015. Renal control of calcium, phosphate, and magnesium 
homeostasis. 
Clin J Am Soc Nephrol, 10,1257 -72.
Cella, D. 1997. Manual of the Functional Assessment of Chronic Illness Therap y (FACIT) 
measurement s ystem. Evanston, IL : Center on Outcomes, Research and Education 
(CORE).
Haussler, M. R. & Cord y, P. E. 1982. Metabolites and analogues of vitamin D. Which for what? 
Jama, 247, 841-4.
Page, C. & Strunski, V. 2007. Parathy roid risk in tota l thyroidectomy  for bilateral, benign, 
multinodular goitre: report of 351 surgical cases. J Laryngol Otol, 121, 237-41.
Powers, J., Joy , K., Ruscio, A. & Lagast, H. 2013. Prevalence and incidence of 
hypoparathy roidism in the United States using a large cla ims database. J Bone Miner Res,
28,2570 -6.
Shoback, D. 2008. Clinical practice. Hy poparathy roidism. N Engl J Med, 359, 391-403.
Thomusch, O., Machens, A., Sekulla, C., Ukkat, J., Brauckhoff, M. & Dralle, H. 2003. The 
impact of surgical technique on postop erative h ypoparath yroidism in bilateral thyroid 
surgery : a multivariate analy sis of 5846 consecutive patients. Surgery, 133, 180-5.
Velasco, P. J., Manshadi, M., Breen, K. & Lippmann, S. 1999. Psy chiatric aspects of parath yroid 
disease. 
Psychosomatics, 40,486-90.
Ware, J. E., Jr. & Sherbourne, C. D. 1992. The MOS 36
-item short- form health survey  (SF-36). 
I. Conceptual framework and item selection. Med Care, 30,473-83.
Zarnegar, R., Brunaud, L. & Clark, O. H. 2003. Prevention, evaluation, and management of
complications following thy roidectomy  for thy roid carcinoma. Endocrinol Metab Clin 
North Am, 32,483-502.
Zigmond, A. S. & Snaith, R. P. 1983. The hospital anxiety  and depression scale. Acta Psychiatr 
Scand, 67,361-70.
Shire 
SHP634-402 Protocol
CONFIDENTIAL 
Page 61 
27 May 2016
 
   
APPENDIX 1 HYPOPARATHYROIDISM S YMPTOM DIARY
Shire 
SHP634-402 Protocol
CONFIDENTIAL 
Page 62 
27 May 2016
,ǇƉŽƉĂƌĂƚŚǇƌŽŝĚŝƐŵ^ǇŵƉƚŽŵŝĂƌǇ
&ŽƌĞĂĐŚŽĨƚŚĞĨŽůůŽǁŝŶŐƋƵĞƐƚŝŽŶƐ͕ƉůĞĂƐĞĐŚŽŽƐĞƚŚĞŽŶĞĂŶƐǁ ĞƌƚŚĂƚďĞƐƚĚĞƐĐƌŝďĞƐǇŽƵƌ
ĞǆƉĞƌŝĞŶĐĞƐƌĞůĂƚĞĚƚŽŚǇƉŽƉĂƌĂƚŚǇƌŽŝĚŝƐŵĚƵƌŝŶŐƚŚĞƉĂƐƚϮϰŚŽ ƵƌƐ͘
ϭ͘,ŽǁǁŽƵůĚǇŽƵƌĂƚĞĂŶǇŵƵƐĐůĞĐƌĂŵƉƐǇŽƵĞǆƉĞƌŝĞŶĐĞĚĚƵƌŝŶŐƚŚ ĞƉĂƐƚϮϰŚŽƵƌƐ͍

Ϭ
ϭ
Ϯ
ϯ
ϰ
ϱ
ϲ
ϳ
ϴ
ϵ
ϭϬ
EŽ tŽƌƐƚ
ŵƵƐĐůĞ ƉŽƐƐŝďůĞĐƌĂŵƉƐ ŵƵƐĐůĞ
ĐƌĂŵƉƐ
Ϯ͘,ŽǁǁŽƵůĚǇŽƵƌĂƚĞĂŶǇƚŝŶŐůŝŶŐǇŽƵĞǆƉĞƌŝĞŶĐĞĚĚƵƌŝŶŐƚŚĞƉ ĂƐƚϮϰŚŽƵƌƐ͍
.EŽŶĞ
DŝůĚ
DŽĚĞƌĂƚĞ
^ĞǀĞƌĞ
sĞƌǇƐĞǀĞƌĞ
ϯ͘,ŽǁǁŽƵůĚǇŽƵƌĂƚĞĂŶǇŶƵŵďŶĞƐƐǇŽƵĞǆƉĞƌŝĞŶĐĞĚĚƵƌŝŶŐƚŚĞƉ ĂƐƚϮϰŚŽƵƌƐ͍
EŽŶĞ
DŝůĚ
DŽĚĞƌĂƚĞ
^ĞǀĞƌĞ
sĞƌǇƐĞǀĞƌĞ6KLUH
6+33URWRFRO&21),'(17,$/ 3DJH
0D\
ϰ͘,ŽǁǁŽƵůĚǇŽƵƌĂƚĞĂŶǇŵƵƐĐůĞƐƉĂƐŵƐŽƌƚǁŝƚĐŚŝŶŐǇŽƵĞǆƉĞƌŝĞŶ ĐĞĚĚƵƌŝŶŐƚŚĞƉĂƐƚϮϰ
ŚŽƵƌƐ͍
EŽŶĞ
DŝůĚ
DŽĚĞƌĂƚĞ
^ĞǀĞƌĞ
sĞƌǇƐĞǀĞƌĞ
ϱ͘,ŽǁǁŽƵůĚǇŽƵƌĂƚĞĂŶǇĨĞĞůŝŶŐƐŽĨŚĞĂǀŝŶĞƐƐǇŽƵĞǆƉĞƌŝĞŶĐĞĚ ŝŶǇŽƵƌĂƌŵƐŽƌůĞŐƐĚƵƌŝŶŐ
ƚŚĞƉĂƐƚϮϰŚŽƵƌƐ͍
EŽŶĞ
DŝůĚ
DŽĚĞƌĂƚĞ
^ĞǀĞƌĞ
sĞƌǇƐĞǀĞƌĞ
ϲ͘,ŽǁǁŽƵůĚǇŽƵƌĂƚĞĂŶǇƉŚǇƐŝĐĂůĨĂƚŝŐƵĞǇŽƵĞǆƉĞƌŝĞŶĐĞĚĚƵƌŝŶ ŐƚŚĞƉĂƐƚϮϰŚŽƵƌƐ͍
EŽŶĞ
DŝůĚ
DŽĚĞƌĂƚĞ
^ĞǀĞƌĞ
sĞƌǇƐĞǀĞƌĞ
ϳ͘,ŽǁǁŽƵůĚǇŽƵƌĂƚĞĂŶǇƐůŽǁĞĚŽƌĐŽŶĨƵƐĞĚƚŚŝŶŬŝŶŐ͕ƐŽŵĞƚŝŵĞ ƐĐĂůůĞĚďƌĂŝŶĨŽŐ͕ǇŽƵ
ĞǆƉĞƌŝĞŶĐĞĚĚƵƌŝŶŐƚŚĞƉĂƐƚϮϰŚŽƵƌƐ͍
EŽŶĞ
DŝůĚ
DŽĚĞƌĂƚĞ
^ĞǀĞƌĞ
sĞƌǇƐĞǀĞƌĞ6KLUH
6+33URWRFRO&21),'(17,$/ 3DJH
0D\
ϴ͘,ŽǁǁŽƵůĚǇŽƵƌĂƚĞĂŶǇĂŶǆŝĞƚǇǇŽƵĨĞůƚĚƵƌŝŶŐƚŚĞƉĂƐƚϮϰŚŽ ƵƌƐ͍
EŽŶĞ
DŝůĚ
DŽĚĞƌĂƚĞ
^ĞǀĞƌĞ
sĞƌǇƐĞǀĞƌĞ
ϵ͘,ŽǁǁŽƵůĚǇŽƵƌĂƚĞĂŶǇƐĂĚŶĞƐƐŽƌĚĞƉƌĞƐƐŝŽŶǇŽƵĨĞůƚĚƵƌŝŶŐ ƚŚĞƉĂƐƚϮϰŚŽƵƌƐ͍
EŽŶĞ
DŝůĚ
DŽĚĞƌĂƚĞ
^ĞǀĞƌĞ
sĞƌǇƐĞǀĞƌĞ
ϭϬ͘,ŽǁĚŝĚǇŽƵƌŚǇƉŽƉĂƌĂƚŚǇƌŽŝĚŝƐŵŝŵƉĂĐƚǇŽƵƌƐůĞĞƉůĂƐƚŶŝŐŚ ƚ͍
EŽƚĂƚĂůů
^ŽŵĞǁŚĂƚ
sĞƌǇŵƵĐŚ
ϭϭ͘,ŽǁĚŝĚǇŽƵƌŚǇƉŽƉĂƌĂƚŚǇƌŽŝĚŝƐŵŝŵƉĂĐƚǇŽƵƌĂďŝůŝƚǇƚŽĞǆĞƌ ĐŝƐĞŝŶƚŚĞƉĂƐƚϮϰŚŽƵƌƐ͍

EŽƚĂƚĂůů
^ŽŵĞǁŚĂƚ
sĞƌǇŵƵĐŚ6KLUH
6+33URWRFRO&21),'(17,$/ 3DJH
0D\
ϭϮ͘,ŽǁĚŝĚǇŽƵƌŚǇƉŽƉĂƌĂƚŚǇƌŽŝĚŝƐŵŝŵƉĂĐƚǇŽƵƌĂďŝůŝƚǇƚŽĐŽŵƉůĞ ƚĞǇŽƵƌǁŽƌŬ;ĨŽƌĞǆĂŵƉůĞ͕
ĂƚƐĐŚŽŽů͕ĂƚŚŽŵĞŽƌĂƚĂũŽďͿŝŶƚŚĞƉĂƐƚϮϰŚŽƵƌƐ͍

EŽƚĂƚĂůů
^ŽŵĞǁŚĂƚ
sĞƌǇŵƵĐŚ
ϭϯ͘,ŽǁĚŝĚǇŽƵƌŚǇƉŽƉĂƌĂƚŚǇƌŽŝĚŝƐŵŝŵƉĂĐƚǇŽƵƌƌĞůĂƚŝŽŶƐŚŝƉƐǁ ŝƚŚǇŽƵƌĨĂŵŝůǇŵĞŵďĞƌƐŝŶ
ƚŚĞƉĂƐƚϮϰŚŽƵƌƐ͍

EŽƚĂƚĂůů
^ŽŵĞǁŚĂƚ
sĞƌǇŵƵĐŚ6KLUH
6+33URWRFRO&21),'(17,$/ 3DJH
0D\
 
   
APPENDIX 2 FACT -COGNITIVE FUNCTION E NG
Shire 
SHP634-402 Protocol
CONFIDENTIAL 
Page 67 
27 May 2016